ELI LILLY & Co - Quarter Report: 2021 September (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
Quarterly Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
For the quarterly period ended September 30, 2021
COMMISSION FILE NUMBER 001-6351
ELI LILLY AND COMPANY
(Exact name of Registrant as specified in its charter)
| Indiana | 35-0470950 | |||||||
| (State or other jurisdiction of | (I.R.S. Employer | |||||||
| incorporation or organization) | Identification No.) | |||||||
Lilly Corporate Center, Indianapolis, Indiana 46285
(Address and zip code of principal executive offices)
Registrant’s telephone number, including area code (317) 276-2000
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of Each Class | Trading Symbols | Name of Each Exchange On Which Registered | ||||||
| Common Stock (no par value) | LLY | New York Stock Exchange | ||||||
| 1.000% Notes due 2022 | LLY22 | New York Stock Exchange | ||||||
| 7 1/8% Notes due 2025 | LLY25 | New York Stock Exchange | ||||||
| 1.625% Notes due 2026 | LLY26 | New York Stock Exchange | ||||||
| 2.125% Notes due 2030 | LLY30 | New York Stock Exchange | ||||||
| 0.625% Notes due 2031 | LLY31 | New York Stock Exchange | ||||||
| 0.500% Notes due 2033 | LLY33 | New York Stock Exchange | ||||||
| 6.77% Notes due 2036 | LLY36 | New York Stock Exchange | ||||||
| 1.625% Notes due 2043 | LLY43 | New York Stock Exchange | ||||||
| 1.700% Notes due 2049 | LLY49A | New York Stock Exchange | ||||||
| 1.125% Notes due 2051 | LLY51 | New York Stock Exchange | ||||||
| 1.375% Notes due 2061 | LLY61 | New York Stock Exchange | ||||||
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☒ | Accelerated filer | ☐ | ||||||||||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | ||||||||||||||||||||
| Emerging growth company | ☐ | ||||||||||||||||||||||
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
The number of shares of common stock outstanding as of October 22, 2021:
| Class | Number of Shares Outstanding | |||||||
| Common | 956,592,393 | |||||||
Eli Lilly and Company
Form 10-Q
For the Quarter Ended September 30, 2021
Table of Contents
| Page | ||||||||||||||
2
Forward-Looking Statements
This Quarterly Report on Form 10-Q and our other publicly available documents include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act), and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. In particular, information appearing under “Management's Discussion and Analysis of Results of Operations and Financial Condition” includes forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “intend,” “anticipate,” “plan,” “continue,” or similar expressions or future or conditional verbs.
Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those expressed in forward-looking statements. Where, in any forward-looking statement, we express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:
•the impact of the evolving COVID-19 pandemic and the global response thereto;
•uncertainties related to our efforts to develop potential treatments for COVID-19;
•the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals;
•the impact of acquisitions and business development transactions and related integration costs;
•the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products;
•our ability to protect and enforce patents and other intellectual property;
•changes in patent law or regulations related to data package exclusivity;
•competitive developments affecting current products and our pipeline;
•market uptake of recently launched products;
•information technology system inadequacies, breaches, or operating failures;
•unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our IT systems, networks, and facilities, or those of third parties with whom we share our data;
•unexpected safety or efficacy concerns associated with our products;
•litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured;
•issues with product supply and regulatory approvals stemming from manufacturing difficulties or disruptions, including as a result of regulatory actions relating to our facilities;
•reliance on third-party relationships and outsourcing arrangements;
•regulatory changes or other developments;
•regulatory actions regarding currently marketed products;
•continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals;
•devaluations in foreign currency exchange rates or changes in interest rates, and inflation;
•changes in tax law, tax rates, or events that differ from our assumptions related to tax positions;
•asset impairments and restructuring charges;
•the impact of global macroeconomic conditions and trade disruptions or disputes;
•changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and
•regulatory compliance problems or government investigations.
More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2020, particularly under the caption “Risk Factors”.
3
All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this Quarterly Report on Form 10-Q. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this Quarterly Report on Form 10-Q.
4
PART I. Financial Information
Item 1. Financial Statements
Consolidated Condensed Statements of Operations
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars and shares in millions, except per-share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Revenue (Note 2) | $ | 6,772.8 | $ | 5,740.6 | $ | 20,318.5 | $ | 17,099.8 | |||||||||||||||
| Costs, expenses, and other: | |||||||||||||||||||||||
| Cost of sales | 1,430.8 | 1,326.4 | 5,262.6 | 3,763.5 | |||||||||||||||||||
| Research and development | 1,708.9 | 1,465.4 | 5,066.5 | 4,247.7 | |||||||||||||||||||
| Marketing, selling, and administrative | 1,577.9 | 1,569.1 | 4,839.6 | 4,567.3 | |||||||||||||||||||
Acquired in-process research and development (Note 3) | 174.0 | — | 498.3 | 294.1 | |||||||||||||||||||
| Asset impairment, restructuring, and other special charges (Note 5) | — | 101.4 | 211.6 | 161.3 | |||||||||||||||||||
| Other–net, (income) expense (Note 11) | 635.9 | (158.9) | 124.3 | (694.9) | |||||||||||||||||||
| 5,527.5 | 4,303.4 | 16,002.9 | 12,339.0 | ||||||||||||||||||||
| Income before income taxes | 1,245.3 | 1,437.2 | 4,315.6 | 4,760.8 | |||||||||||||||||||
| Income taxes (Note 7) | 135.2 | 228.8 | 460.0 | 683.9 | |||||||||||||||||||
| Net income | $ | 1,110.1 | $ | 1,208.4 | $ | 3,855.6 | $ | 4,076.9 | |||||||||||||||
| Earnings per share: | |||||||||||||||||||||||
| Basic | $ | 1.22 | $ | 1.33 | $ | 4.25 | $ | 4.49 | |||||||||||||||
| Diluted | $ | 1.22 | $ | 1.33 | $ | 4.23 | $ | 4.47 | |||||||||||||||
| Shares used in calculation of earnings per share: | |||||||||||||||||||||||
| Basic | 906.7 | 907.2 | 907.7 | 907.5 | |||||||||||||||||||
| Diluted | 910.8 | 911.4 | 911.7 | 911.9 | |||||||||||||||||||
See notes to consolidated condensed financial statements.
5
Consolidated Condensed Statements of Comprehensive Income (Loss)
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Net income | $ | 1,110.1 | $ | 1,208.4 | $ | 3,855.6 | $ | 4,076.9 | |||||||||||||||
| Other comprehensive income (loss), net of tax (Note 10) | 114.4 | 127.8 | 323.7 | (31.5) | |||||||||||||||||||
| Comprehensive income | $ | 1,224.5 | $ | 1,336.2 | $ | 4,179.3 | $ | 4,045.4 | |||||||||||||||
See notes to consolidated condensed financial statements.
6
Consolidated Condensed Balance Sheets
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
| September 30, 2021 | December 31, 2020 | ||||||||||
| Assets | (Unaudited) | ||||||||||
| Current Assets | |||||||||||
| Cash and cash equivalents (Note 6) | $ | 3,788.2 | $ | 3,657.1 | |||||||
| Short-term investments (Note 6) | 37.1 | 24.2 | |||||||||
Accounts receivable, net of allowances of $24.1 (2021) and $25.9 (2020) | 5,914.3 | 5,875.3 | |||||||||
| Other receivables | 1,110.7 | 1,053.7 | |||||||||
| Inventories | 3,907.4 | 3,980.3 | |||||||||
| Prepaid expenses and other | 3,050.6 | 2,871.5 | |||||||||
| Total current assets | 17,808.3 | 17,462.1 | |||||||||
| Investments (Note 6) | 3,350.5 | 2,966.8 | |||||||||
| Goodwill | 3,884.1 | 3,766.5 | |||||||||
| Other intangibles, net | 7,887.7 | 7,450.0 | |||||||||
| Deferred tax assets | 2,625.6 | 2,830.4 | |||||||||
Property and equipment, net of accumulated depreciation of $9,962.8 (2021) and $9,570.7 (2020) | 8,920.4 | 8,681.9 | |||||||||
| Other noncurrent assets | 3,710.4 | 3,475.4 | |||||||||
| Total assets | $ | 48,187.0 | $ | 46,633.1 | |||||||
| Liabilities and Equity | |||||||||||
| Current Liabilities | |||||||||||
| Short-term borrowings and current maturities of long-term debt | $ | 1,563.0 | $ | 8.7 | |||||||
| Accounts payable | 1,566.8 | 1,606.7 | |||||||||
| Employee compensation | 836.6 | 997.2 | |||||||||
| Sales rebates and discounts | 7,185.6 | 5,853.0 | |||||||||
| Dividends payable | — | 770.6 | |||||||||
| Income taxes payable | 203.5 | 495.1 | |||||||||
| Other current liabilities | 2,326.5 | 2,750.3 | |||||||||
| Total current liabilities | 13,682.0 | 12,481.6 | |||||||||
| Other Liabilities | |||||||||||
| Long-term debt | 15,522.4 | 16,586.6 | |||||||||
| Accrued retirement benefits (Note 8) | 3,878.8 | 4,094.5 | |||||||||
| Long-term income taxes payable | 3,768.5 | 3,837.8 | |||||||||
| Deferred tax liabilities | 1,632.5 | 2,099.9 | |||||||||
| Other noncurrent liabilities | 1,748.7 | 1,707.5 | |||||||||
| Total other liabilities | 26,550.9 | 28,326.3 | |||||||||
| Commitments and Contingencies (Note 9) | |||||||||||
| Eli Lilly and Company Shareholders’ Equity | |||||||||||
| Common stock | 598.2 | 598.2 | |||||||||
| Additional paid-in capital | 6,758.0 | 6,778.5 | |||||||||
| Retained earnings | 9,639.4 | 7,830.2 | |||||||||
| Employee benefit trust | (3,013.2) | (3,013.2) | |||||||||
| Accumulated other comprehensive loss (Note 10) | (6,172.7) | (6,496.4) | |||||||||
| Cost of common stock in treasury | (52.7) | (55.7) | |||||||||
| Total Eli Lilly and Company shareholders’ equity | 7,757.0 | 5,641.6 | |||||||||
| Noncontrolling interests | 197.1 | 183.6 | |||||||||
| Total equity | 7,954.1 | 5,825.2 | |||||||||
| Total liabilities and equity | $ | 48,187.0 | $ | 46,633.1 | |||||||
See notes to consolidated condensed financial statements.
7
Consolidated Condensed Statements of Equity
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
| Equity of Eli Lilly and Company Shareholders | |||||||||||||||||||||||||||||||||||||||||||||||||||||
(Dollars in millions, except per-share data, and shares in thousands) | Common Stock | Additional Paid-in Capital | Retained Earnings | Employee Benefit Trust | Accumulated Other Comprehensive Loss | Common Stock in Treasury(1) | Noncontrolling Interests | ||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at July 1, 2020 | 956,953 | $ | 598.1 | $ | 6,629.4 | $ | 6,617.2 | $ | (3,013.2) | $ | (6,682.9) | 487 | $ | (55.7) | $ | 179.1 | |||||||||||||||||||||||||||||||||||||
| Net income (loss) | 1,208.4 | (4.8) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | 127.8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash dividends declared per share: $0.74 | (671.6) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of stock under employee stock plans, net | 25 | — | (2.3) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | 71.7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | (5.2) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2020 | 956,978 | $ | 598.1 | $ | 6,698.8 | $ | 7,154.0 | $ | (3,013.2) | $ | (6,555.1) | 487 | $ | (55.7) | $ | 169.1 | |||||||||||||||||||||||||||||||||||||
| Balance at July 1, 2021 | 957,038 | $ | 598.1 | $ | 6,669.2 | $ | 8,530.1 | $ | (3,013.2) | $ | (6,287.1) | 463 | $ | (52.7) | $ | 219.1 | |||||||||||||||||||||||||||||||||||||
| Net income (loss) | 1,110.1 | (22.6) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | 114.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of stock under employee stock plans, net | 14 | 0.1 | (1.3) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | 90.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | (0.8) | 0.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2021 | 957,052 | $ | 598.2 | $ | 6,758.0 | $ | 9,639.4 | $ | (3,013.2) | $ | (6,172.7) | 463 | $ | (52.7) | $ | 197.1 | |||||||||||||||||||||||||||||||||||||
(1) As of September 30, 2021, there were $500.0 million remaining under our $8.00 billion share repurchase program authorized in June 2018 and $5.00 billion remaining under our $5.00 billion share repurchase program authorized in May 2021.
See notes to consolidated condensed financial statements.
8
| Equity of Eli Lilly and Company Shareholders | |||||||||||||||||||||||||||||||||||||||||||||||||||||
(Dollars in millions, except per-share data, and shares in thousands) | Common Stock | Additional Paid-in Capital | Retained Earnings | Employee Benefit Trust | Accumulated Other Comprehensive Loss | Common Stock in Treasury(1) | Noncontrolling Interests | ||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at January 1, 2020 | 958,056 | $ | 598.8 | $ | 6,685.3 | $ | 4,920.4 | $ | (3,013.2) | $ | (6,523.6) | 530 | $ | (60.8) | $ | 92.2 | |||||||||||||||||||||||||||||||||||||
| Net income | 4,076.9 | 95.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss, net of tax | (31.5) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash dividends declared per share: $1.48 | (1,345.6) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Retirement of treasury shares | (3,627) | (2.3) | (497.7) | (3,627) | 500.0 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Purchase of treasury shares | 3,627 | (500.0) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of stock under employee stock plans, net | 2,549 | 1.6 | (206.4) | (43) | 5.1 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | 220.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | (0.4) | (19.0) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2020 | 956,978 | $ | 598.1 | $ | 6,698.8 | $ | 7,154.0 | $ | (3,013.2) | $ | (6,555.1) | 487 | $ | (55.7) | $ | 169.1 | |||||||||||||||||||||||||||||||||||||
| Balance at January 1, 2021 | 957,077 | $ | 598.2 | $ | 6,778.5 | $ | 7,830.2 | $ | (3,013.2) | $ | (6,496.4) | 487 | $ | (55.7) | $ | 183.6 | |||||||||||||||||||||||||||||||||||||
| Net income | 3,855.6 | 25.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | 323.7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash dividends declared per share: $1.70 | (1,542.9) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Retirement of treasury shares | (2,467) | (1.5) | (498.5) | (2,467) | 500.0 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Purchase of treasury shares | 2,467 | (500.0) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of stock under employee stock plans, net | 2,442 | 1.5 | (287.1) | (24) | 3.0 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | 267.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other | (0.9) | (5.0) | (11.7) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2021 | 957,052 | $ | 598.2 | $ | 6,758.0 | $ | 9,639.4 | $ | (3,013.2) | $ | (6,172.7) | 463 | $ | (52.7) | $ | 197.1 | |||||||||||||||||||||||||||||||||||||
(1) As of September 30, 2021, there were $500.0 million remaining under our $8.00 billion share repurchase program authorized in June 2018 and $5.00 billion remaining under our $5.00 billion share repurchase program authorized in May 2021.
See notes to consolidated condensed financial statements.
9
Consolidated Condensed Statements of Cash Flows
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
| Nine Months Ended September 30, | |||||||||||
| 2021 | 2020 | ||||||||||
| Cash Flows from Operating Activities | |||||||||||
| Net income | $ | 3,855.6 | $ | 4,076.9 | |||||||
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: | |||||||||||
| Depreciation and amortization | 1,101.9 | 956.4 | |||||||||
| Change in deferred income taxes | (709.8) | 66.2 | |||||||||
| Debt extinguishment loss (Note 6) | 405.2 | — | |||||||||
| Stock-based compensation expense | 267.5 | 220.3 | |||||||||
| Net investment gains | (271.1) | (909.5) | |||||||||
| Acquired in-process research and development (Note 3) | 498.3 | 294.1 | |||||||||
Other changes in operating assets and liabilities, net of acquisitions and divestitures | (548.1) | (232.2) | |||||||||
| Other non-cash operating activities, net | 504.7 | 212.2 | |||||||||
| Net Cash Provided by Operating Activities | 5,104.2 | 4,684.4 | |||||||||
| Cash Flows from Investing Activities | |||||||||||
| Net purchases of property and equipment | (1,018.4) | (933.2) | |||||||||
| Proceeds from sales and maturities of short-term investments | 46.6 | 118.8 | |||||||||
| Purchases of short-term investments | (27.9) | (11.4) | |||||||||
| Proceeds from sales of noncurrent investments | 537.2 | 574.1 | |||||||||
| Purchases of noncurrent investments | (710.1) | (223.7) | |||||||||
| Cash paid for acquisitions, net of cash acquired (Note 3) | (747.4) | (849.3) | |||||||||
| Purchases of in-process research and development | (460.6) | (276.4) | |||||||||
| Other investing activities, net | (2.7) | 16.3 | |||||||||
| Net Cash Used for Investing Activities | (2,383.3) | (1,584.8) | |||||||||
| Cash Flows from Financing Activities | |||||||||||
| Dividends paid | (2,313.5) | (2,017.1) | |||||||||
| Net change in short-term borrowings | (1.5) | (914.3) | |||||||||
| Proceeds from issuance of long-term debt | 2,410.8 | 2,062.3 | |||||||||
| Repayments of long-term debt | (1,905.3) | (276.3) | |||||||||
| Purchases of common stock | (500.0) | (500.0) | |||||||||
| Other financing activities, net | (295.3) | (200.2) | |||||||||
| Net Cash Used for Financing Activities | (2,604.8) | (1,845.6) | |||||||||
| Effect of exchange rate changes on cash and cash equivalents | 15.0 | 3.8 | |||||||||
| Net increase in cash and cash equivalents | 131.1 | 1,257.8 | |||||||||
| Cash and cash equivalents at January 1 | 3,657.1 | 2,337.5 | |||||||||
| Cash and Cash Equivalents at September 30 | $ | 3,788.2 | $ | 3,595.3 | |||||||
See notes to consolidated condensed financial statements.
10
Notes to Consolidated Condensed Financial Statements
(Tables present dollars in millions, except per-share data)
Note 1: Basis of Presentation
We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the consolidated condensed financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2020. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of this Quarterly Report on Form 10-Q.
All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis; that is, based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.
We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.
11
Note 2: Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Net product revenue | $ | 6,189.0 | $ | 5,281.1 | $ | 18,579.5 | $ | 15,762.3 | |||||||||||||||
Collaboration and other revenue (1) | 583.8 | 459.5 | 1,739.0 | 1,337.5 | |||||||||||||||||||
| Revenue | $ | 6,772.8 | $ | 5,740.6 | $ | 20,318.5 | $ | 17,099.8 | |||||||||||||||
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $62.1 million and $136.1 million during the three and nine months ended September 30, 2021, respectively, and $31.5 million and $101.5 million during the three and nine months ended September 30, 2020, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Jardiance® and Trajenta® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Adjustments to Revenue
Adjustments to increase (decrease) revenue recognized as a result of changes in estimates for our most significant United States (U.S.) sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 1 percent of U.S. revenue during each of the three and nine months ended September 30, 2021, and approximately (1) percent and 1 percent of U.S. revenue for the three and nine months ended September 30, 2020, respectively.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
The following table summarizes contract liability balances:
| September 30, 2021 | December 31, 2020 | ||||||||||
| Contract liabilities | $ | 278.4 | $ | 276.8 | |||||||
During the three and nine months ended September 30, 2021 and 2020, revenue recognized from contract liabilities as of the beginning of the respective year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.
12
Disaggregation of Revenue
The following table summarizes revenue by product for the three months ended September 30, 2021 and 2020:
| Three Months Ended September 30, | |||||||||||||||||||||||
| 2021 | 2020 | ||||||||||||||||||||||
U.S. | Outside U.S. | Total | U.S. | Outside U.S. | Total | ||||||||||||||||||
| Revenue—to unaffiliated customers: | |||||||||||||||||||||||
| Diabetes: | |||||||||||||||||||||||
Trulicity® | $ | 1,201.4 | $ | 398.8 | $ | 1,600.1 | $ | 791.2 | $ | 315.4 | $ | 1,106.6 | |||||||||||
Humalog® (1) | 347.3 | 279.4 | 626.7 | 390.1 | 266.9 | 656.9 | |||||||||||||||||
Jardiance (2) | 221.2 | 169.2 | 390.4 | 163.3 | 147.5 | 310.8 | |||||||||||||||||
Humulin® | 193.4 | 93.4 | 286.7 | 214.0 | 91.9 | 305.9 | |||||||||||||||||
Basaglar® | 114.7 | 78.1 | 192.8 | 178.5 | 69.7 | 248.2 | |||||||||||||||||
| Other Diabetes | 65.0 | 112.2 | 177.4 | 61.4 | 93.1 | 154.6 | |||||||||||||||||
| Total Diabetes | 2,143.0 | 1,131.1 | 3,274.1 | 1,798.5 | 984.5 | 2,783.0 | |||||||||||||||||
| Oncology: | |||||||||||||||||||||||
Alimta® | 297.2 | 159.8 | 457.0 | 291.9 | 286.1 | 578.0 | |||||||||||||||||
Verzenio® | 199.6 | 135.9 | 335.5 | 158.9 | 75.5 | 234.4 | |||||||||||||||||
Cyramza® | 84.8 | 168.6 | 253.4 | 94.5 | 158.2 | 252.7 | |||||||||||||||||
Erbitux® | 114.0 | 20.3 | 134.3 | 122.5 | 14.0 | 136.4 | |||||||||||||||||
Tyvyt® | — | 125.6 | 125.6 | — | 84.4 | 84.4 | |||||||||||||||||
| Other Oncology | 35.3 | 65.1 | 100.3 | 14.7 | 32.7 | 47.5 | |||||||||||||||||
| Total Oncology | 730.9 | 675.3 | 1,406.1 | 682.5 | 650.9 | 1,333.4 | |||||||||||||||||
| Immunology: | |||||||||||||||||||||||
Taltz® | 422.2 | 170.9 | 593.1 | 326.2 | 128.3 | 454.5 | |||||||||||||||||
Olumiant® (3) | 194.0 | 212.9 | 406.9 | 14.5 | 147.5 | 162.0 | |||||||||||||||||
| Other Immunology | — | 4.9 | 4.9 | 6.1 | 4.5 | 10.6 | |||||||||||||||||
| Total Immunology | 616.2 | 388.7 | 1,004.9 | 346.8 | 280.3 | 627.1 | |||||||||||||||||
| Neuroscience: | |||||||||||||||||||||||
Emgality® | 99.9 | 40.1 | 140.0 | 81.4 | 10.1 | 91.5 | |||||||||||||||||
Cymbalta® | 7.0 | 125.1 | 132.0 | 11.1 | 175.5 | 186.6 | |||||||||||||||||
Zyprexa® | 13.0 | 88.7 | 101.7 | 21.2 | 91.5 | 112.7 | |||||||||||||||||
| Other Neuroscience | 24.7 | 51.6 | 76.5 | 26.7 | 53.2 | 79.9 | |||||||||||||||||
| Total Neuroscience | 144.6 | 305.5 | 450.2 | 140.4 | 330.3 | 470.7 | |||||||||||||||||
| Other: | |||||||||||||||||||||||
COVID-19 Antibodies (4) | 215.5 | 1.6 | 217.1 | — | — | — | |||||||||||||||||
Forteo® | 109.6 | 91.3 | 200.9 | 144.6 | 122.3 | 266.9 | |||||||||||||||||
Cialis® | (6.5) | 137.4 | 130.9 | 15.1 | 147.3 | 162.5 | |||||||||||||||||
| Other | 36.3 | 52.4 | 88.8 | 33.5 | 63.6 | 97.0 | |||||||||||||||||
| Total Other | 354.9 | 282.7 | 637.7 | 193.2 | 333.2 | 526.4 | |||||||||||||||||
| Revenue | $ | 3,989.6 | $ | 2,783.3 | $ | 6,772.8 | $ | 3,161.4 | $ | 2,579.3 | $ | 5,740.6 | |||||||||||
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(3) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA).
(4) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.
13
The following table summarizes revenue by product for the nine months ended September 30, 2021 and 2020:
| Nine Months Ended September 30, | |||||||||||||||||||||||
| 2021 | 2020 | ||||||||||||||||||||||
| U.S. | Outside U.S. | Total | U.S. | Outside U.S. | Total | ||||||||||||||||||
| Revenue—to unaffiliated customers: | |||||||||||||||||||||||
| Diabetes: | |||||||||||||||||||||||
| Trulicity | $ | 3,465.7 | $ | 1,122.5 | $ | 4,588.2 | $ | 2,673.2 | $ | 892.5 | $ | 3,565.7 | |||||||||||
Humalog (1) | 1,009.0 | 842.3 | 1,851.3 | 1,070.4 | 837.4 | 1,907.8 | |||||||||||||||||
Jardiance (2) | 566.8 | 492.1 | 1,058.9 | 453.0 | 387.3 | 840.3 | |||||||||||||||||
| Humulin | 633.5 | 290.3 | 923.8 | 642.5 | 292.7 | 935.2 | |||||||||||||||||
| Basaglar | 423.3 | 226.8 | 650.1 | 638.7 | 203.7 | 842.3 | |||||||||||||||||
| Other Diabetes | 185.7 | 302.6 | 488.3 | 185.2 | 254.4 | 439.6 | |||||||||||||||||
| Total Diabetes | 6,284.0 | 3,276.6 | 9,560.6 | 5,663.0 | 2,868.0 | 8,530.9 | |||||||||||||||||
| Oncology: | |||||||||||||||||||||||
| Alimta | 911.9 | 714.7 | 1,626.6 | 933.4 | 743.8 | 1,677.2 | |||||||||||||||||
| Verzenio | 582.1 | 363.7 | 945.8 | 430.0 | 201.1 | 631.1 | |||||||||||||||||
| Cyramza | 266.3 | 496.3 | 762.5 | 277.6 | 470.8 | 748.4 | |||||||||||||||||
| Erbitux | 357.7 | 45.9 | 403.7 | 356.1 | 40.6 | 396.7 | |||||||||||||||||
| Tyvyt | — | 340.2 | 340.2 | — | 205.9 | 205.9 | |||||||||||||||||
| Other Oncology | 83.7 | 169.9 | 253.6 | 26.0 | 118.2 | 144.2 | |||||||||||||||||
| Total Oncology | 2,201.7 | 2,130.7 | 4,332.4 | 2,023.1 | 1,780.4 | 3,803.5 | |||||||||||||||||
| Immunology: | |||||||||||||||||||||||
| Taltz | 1,071.6 | 493.8 | 1,565.4 | 942.9 | 350.3 | 1,293.2 | |||||||||||||||||
Olumiant (3) | 236.5 | 572.6 | 809.1 | 39.0 | 407.7 | 446.7 | |||||||||||||||||
| Other Immunology | 15.2 | 14.5 | 29.7 | 13.2 | 8.1 | 21.3 | |||||||||||||||||
| Total Immunology | 1,323.3 | 1,080.9 | 2,404.2 | 995.1 | 766.1 | 1,761.2 | |||||||||||||||||
| Neuroscience: | |||||||||||||||||||||||
| Cymbalta | 30.3 | 454.0 | 484.3 | 30.5 | 546.5 | 576.9 | |||||||||||||||||
| Emgality | 313.5 | 102.2 | 415.7 | 229.3 | 23.6 | 252.9 | |||||||||||||||||
| Zyprexa | 28.3 | 264.5 | 292.8 | 41.5 | 266.2 | 307.7 | |||||||||||||||||
| Other Neuroscience | 81.0 | 154.0 | 235.0 | 53.4 | 165.7 | 219.2 | |||||||||||||||||
| Total Neuroscience | 453.1 | 974.7 | 1,427.8 | 354.7 | 1,002.0 | 1,356.7 | |||||||||||||||||
| Other: | |||||||||||||||||||||||
COVID-19 Antibodies (4) | 949.5 | 226.7 | 1,176.2 | — | — | — | |||||||||||||||||
| Forteo | 330.1 | 287.7 | 617.8 | 386.7 | 405.2 | 791.9 | |||||||||||||||||
| Cialis | (3.1) | 541.8 | 538.7 | 64.6 | 421.6 | 486.2 | |||||||||||||||||
| Other | 96.5 | 164.3 | 260.8 | 144.2 | 225.2 | 369.4 | |||||||||||||||||
| Total Other | 1,373.0 | 1,220.5 | 2,593.5 | 595.5 | 1,052.0 | 1,647.5 | |||||||||||||||||
| Revenue | $ | 11,635.1 | $ | 8,683.4 | $ | 20,318.5 | $ | 9,631.4 | $ | 7,468.5 | $ | 17,099.8 | |||||||||||
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
(3) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.
(4) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.
14
The following table summarizes revenue by geographical area:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Revenue—to unaffiliated customers (1): | |||||||||||||||||||||||
| U.S. | $ | 3,989.6 | $ | 3,161.4 | $ | 11,635.1 | $ | 9,631.4 | |||||||||||||||
| Europe | 1,098.6 | 1,046.7 | 3,629.6 | 2,984.4 | |||||||||||||||||||
| Japan | 595.0 | 660.1 | 1,832.2 | 1,919.1 | |||||||||||||||||||
| China | 400.3 | 289.1 | 1,285.0 | 796.2 | |||||||||||||||||||
| Other foreign countries | 689.4 | 583.2 | 1,936.7 | 1,768.7 | |||||||||||||||||||
| Revenue | $ | 6,772.8 | $ | 5,740.6 | $ | 20,318.5 | $ | 17,099.8 | |||||||||||||||
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
Note 3: Acquisitions
In January 2021 and February 2020, we completed the acquisitions of Prevail Therapeutics Inc. (Prevail) and Dermira, Inc. (Dermira), respectively. These transactions, as further discussed in this note below in Acquisitions of Businesses, were accounted for as business combinations under the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated condensed financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition.
We also acquired assets in development which are further discussed in this note below in Asset Acquisitions. Upon each acquisition, the cost allocated to acquired in-process research and development (IPR&D) was immediately expensed because the compound had no alternative future use. We recognized acquired IPR&D charges of $174.0 million and $498.3 million for the three and nine months ended September 30, 2021, respectively, and $294.1 million for the nine months ended September 30, 2020. There were no acquired IPR&D charges recognized in the three months ended September 30, 2020.
Acquisitions of Businesses
Prevail Acquisition
Overview of Transaction
In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy or Spain. To achieve the full value of the CVR, such regulatory approval must occur by December 31, 2024. If such regulatory approval occurs after December 31, 2024, the value of the CVR will be reduced by approximately 8.3 cents per month until December 1, 2028, at which point the CVR will expire without payment.
Under the terms of the agreement, we acquired potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition establishes a new modality for drug discovery and development, extending our research efforts through the creation of a gene therapy program that is being anchored by Prevail’s portfolio of assets. The lead gene therapies in clinical development that we acquired were PR001 for patients with Parkinson’s disease with GBA1 mutations and neuronopathic Gaucher disease and PR006 for patients with frontotemporal dementia with GRN mutations. Both PR001 and PR006 were granted Fast Track designation from the U.S. Food and Drug Administration (FDA).
15
Assets Acquired and Liabilities Assumed
Our access to Prevail information was limited prior to the acquisition. As a consequence, we are in the process of determining fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized.
The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
| Estimated Fair Value at January 22, 2021 | |||||
| Cash | $ | 90.5 | |||
Acquired IPR&D(1) | 824.0 | ||||
Goodwill(2) | 118.8 | ||||
| Deferred tax liabilities | (98.0) | ||||
| Other assets and liabilities, net | (31.5) | ||||
| Acquisition date fair value of consideration transferred | 903.8 | ||||
| Less: | |||||
| Cash acquired | (90.5) | ||||
Fair value of CVR liability(3) | (65.9) | ||||
| Cash paid, net of cash acquired | $ | 747.4 | |||
(1) Acquired IPR&D intangibles primarily relate to PR001.
(2) The goodwill recognized from this acquisition is not deductible for tax purposes.
(3) See Note 6 for a discussion on the estimation of the CVR liability.
Pro forma information has not been included as this acquisition did not have a material impact on our consolidated condensed statements of operations for the three and nine months ended September 30, 2021 and 2020.
Dermira Acquisition
Overview of Transaction
In February 2020, we acquired all shares of Dermira for a purchase price of approximately $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza® (glycopyrronium) cloth, a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the nine months ended September 30, 2021, we sold the rights to Qbrexza. See Note 5 for additional information.
Assets Acquired and Liabilities Assumed
The fair values recognized related to the assets acquired and liabilities assumed in this acquisition included goodwill of $86.8 million, other intangibles of $1.20 billion primarily related to lebrikizumab, deferred income tax liabilities of $49.5 million, and long-term debt of $375.5 million. After the acquisition, we repaid $276.2 million of long-term debt assumed as part of our acquisition of Dermira.
16
Asset Acquisitions
The following table summarizes our asset acquisitions during the nine months ended September 30, 2021 and 2020:
| Counterparty | Compound(s) or Therapy | Acquisition Month | Phase of Development (1) | Acquired IPR&D Expense | ||||||||||||||||
| Precision Biosciences, Inc. | Potential in vivo therapies for genetic disorders | January 2021 | Pre-clinical | $ | 107.8 | |||||||||||||||
| Merus N.V. | CD3-engaging T-cell re-directing bispecific antibodies for the potential treatment of cancer | January 2021 | Pre-clinical | 46.5 | ||||||||||||||||
| Asahi Kasei Pharma Corporation | AK1780, an orally bioavailable P2X7 receptor antagonist for the potential treatment of chronic pain conditions | January 2021 | Phase I | 20.0 | ||||||||||||||||
| Rigel Pharmaceuticals, Inc. | R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases | March 2021 | Phase I | 125.0 | ||||||||||||||||
| MiNA Therapeutics Limited | Pre-clinical targets that could lead to potential new medicines | May 2021 | Pre-clinical | 25.0 | ||||||||||||||||
| Protomer Technologies Inc. | Glucose-sensing insulin program | July 2021 | Pre-clinical | 57.3 | ||||||||||||||||
| Kumquat Biosciences Inc. | Pre-clinical small molecules that stimulate tumor-specific immune responses | July 2021 | Pre-clinical | 55.0 | ||||||||||||||||
| Lycia Therapeutics, Inc. | Several potential modalities across a spectrum of therapeutic areas and diseases | August 2021 | Pre-clinical | 35.0 | ||||||||||||||||
| ProQR Therapeutics N.V. | Pre-clinical targets that could lead to potential new medicines for genetic disorders in the liver and nervous system | September 2021 | Pre-clinical | 26.7 | ||||||||||||||||
| Sitryx Therapeutics Limited | Pre-clinical targets that could lead to potential new medicines for autoimmune diseases | March 2020 | Pre-clinical | 52.3 | ||||||||||||||||
AbCellera Biologics Inc. (AbCellera)(2) | Neutralizing antibodies for the treatment and prevention of COVID-19 | March 2020 | Pre-clinical | 25.0 | ||||||||||||||||
| Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) | Neutralizing antibodies for the treatment and prevention of COVID-19 | May 2020 | Pre-clinical | 20.0 | ||||||||||||||||
| Petra Pharma Corporation (Petra) | Mutant-selective PI3Kα inhibitor that could lead to potential new medicine | May 2020 | Pre-clinical | 174.8 | ||||||||||||||||
| Evox Therapeutics Limited | Pre-clinical targets for the potential treatment of neurological disorders | June 2020 | Pre-clinical | 22.0 | ||||||||||||||||
(1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.
(2) We recognized an acquired IPR&D expense of $25.0 million in May 2020 upon closing of the transaction.
In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.
17
Note 4: Collaborations and Other Arrangements
We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone as well as royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. See Note 2 for amounts of collaboration and other revenue recognized from these types of arrangements.
Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below.
Boehringer Ingelheim Diabetes Collaboration
We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently included in the collaboration are Boehringer Ingelheim’s oral diabetes products: Jardiance, Glyxambi, Synjardy, Trijardy XR, Trajenta, and Jentadueto® as well as our basal insulin, Basaglar. Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family. Jentadueto is included in the Trajenta product family.
The table below summarizes the net amount of significant milestones capitalized (deferred) at September 30, 2021 and December 31, 2020 for the compounds included in this collaboration:
Net Milestones Capitalized (Deferred) (1) as of: | ||||||||
| Product Family | September 30, 2021 | December 31, 2020 | ||||||
Jardiance (2) | $ | 141.1 | $ | 156.2 | ||||
Trajenta (3) | 95.1 | 114.6 | ||||||
| Basaglar | (154.0) | (168.0) | ||||||
(1) In connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. In connection with the regulatory approvals of Basaglar, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.
(2) The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
(3) The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
For the Jardiance product family, we and Boehringer Ingelheim share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of Boehringer Ingelheim's products in the most significant markets and recognize the royalty as collaboration and other revenue. Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family. Beginning January 1, 2021, the royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds. We pay to Boehringer Ingelheim a royalty on net sales for Basaglar in the U.S. We record our sales of Basaglar to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.
The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and our net product revenue recognized with respect to Basaglar:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| Product Family | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
| Jardiance | $ | 390.4 | $ | 310.8 | $ | 1,058.9 | $ | 840.3 | |||||||||||||||
| Basaglar | 192.8 | 248.2 | 650.1 | 842.3 | |||||||||||||||||||
| Trajenta | 96.1 | 91.7 | 279.9 | 261.7 | |||||||||||||||||||
18
Olumiant
We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as Olumiant (baricitinib), and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double digit royalty payments on global net sales with rates ranging up to 20 percent. The agreement calls for payments by us to Incyte associated with certain development, success-based regulatory, and sales-based milestones. In 2020, the agreement was amended to include the treatment of COVID-19, with Incyte obtaining the right to receive an additional royalty ranging up to the low teens on global net sales for the treatment of COVID-19 that exceed a specified aggregate global net sales threshold.
In connection with the regulatory approvals of Olumiant in the U.S., Europe, and Japan, milestone payments of $210.0 million were capitalized as intangible assets as of September 30, 2021 and December 31, 2020 and are being amortized to cost of sales through the term of the collaboration. This represents the cumulative amounts that have been capitalized from the start of this collaboration through the end of each reporting period.
As of September 30, 2021, Incyte is eligible to receive up to $100.0 million of additional payments from us contingent upon certain success-based regulatory milestones. Incyte is also eligible to receive up to $150.0 million of potential sales-based milestones.
We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales. The following table summarizes our net product revenue recognized with respect to Olumiant:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Olumiant | $ | 406.9 | $ | 162.0 | $ | 809.1 | $ | 446.7 | |||||||||||||||
COVID-19 antibodies
In 2020, we entered into a worldwide license and collaboration agreement with AbCellera to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab, for which we hold development and commercialization rights. AbCellera has the right to receive tiered royalty payments on global net sales of bamlanivimab with percentages ranging in the mid-teens to mid-twenties. Royalty payments made to AbCellera are recorded as cost of sales.
In 2020, we entered into a license and collaboration agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including etesevimab, for which we hold development and commercialization rights outside of mainland China and the Special Administrative Regions of Hong Kong and Macau, and for which Junshi Biosciences currently maintains all rights in mainland China and the Special Administrative Regions of Hong Kong and Macau. Junshi Biosciences has the right to receive royalty payments in the mid-teens on our net sales of etesevimab. Junshi Biosciences also has the right to receive certain development, success-based regulatory and sales-based milestones. In connection with the regulatory authorizations of etesevimab (for administration with bamlanivimab) as well as achievement of a sales-based milestone, milestone payments of $95.0 million were capitalized as intangible assets as of September 30, 2021 and are being amortized to cost of sales over the estimated useful life of etesevimab. As of September 30, 2021, Junshi Biosciences is eligible to receive up to $100.0 million of potential sales-based milestones.
Pursuant to EUAs, we recognized $217.1 million and $1.18 billion of net product revenue associated with our sales of our COVID-19 antibodies during the three and nine months ended September 30, 2021, respectively.
Sintilimab Injection
We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt. In 2019, we and Innovent began co-commercializing Tyvyt in China. In 2020, we obtained an exclusive license for sintilimab injection from Innovent for geographies outside of China. Innovent, with collaboration from us, has filed the initial registration of sintilimab injection in the U.S., and we will pursue initial registration of sintilimab injection in other markets and all other subsequent registrations of sintilimab injection. We have exclusive commercialization rights outside of China.
In connection with a regulatory approval for Tyvyt in China in the second quarter of 2021, we capitalized a milestone payment of $40.0 million as an intangible asset which is being amortized to cost of sales through the term of the collaboration.
19
As of September 30, 2021, Innovent is eligible to receive up to $825.0 million for geographies outside of China and up to $195.0 million in China in success-based regulatory and sales-based milestones. Innovent is also eligible to receive tiered double digit royalties on net sales for geographies outside of China.
We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties. The following table summarizes our revenue recognized in China with respect to Tyvyt:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Tyvyt | $ | 125.6 | $ | 84.4 | $ | 340.2 | $ | 205.9 | |||||||||||||||
Tanezumab
We have a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain. In October 2021, we and Pfizer discontinued the global clinical development program of tanezumab for the treatment of osteoarthritis pain and cancer pain following the receipt of a Complete Response Letter from the FDA and a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.
Lebrikizumab
As a result of our acquisition of Dermira, we have a worldwide licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively Roche), which provides us the global development and commercialization rights to lebrikizumab. Roche has the right to receive tiered royalty payments on future global net sales ranging in percentages from high single digits to high teens if the product is successfully commercialized. As of September 30, 2021, Roche is eligible to receive up to $180.0 million of payments from us contingent upon the achievement of success-based regulatory milestones and up to $1.03 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.
As a result of our acquisition of Dermira, we have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize lebrikizumab for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe. We have the right to receive tiered royalty payments on future net sales in Europe ranging in percentages from low double digits to low twenties if the product is successfully commercialized. As of September 30, 2021, we are eligible to receive additional payments of $85.0 million from Almirall contingent upon the achievement of success-based regulatory milestones and up to $1.25 billion in a series of sales-based milestones, contingent upon the commercial success of lebrikizumab.
As of September 30, 2021 and December 31, 2020, $15.3 million and $29.7 million, respectively, were recorded as contract liabilities on the consolidated condensed balance sheets and are expected to be recognized as collaboration and other revenue over the remaining Phase III development period. During the three and nine months ended September 30, 2021 and 2020, milestones received and collaboration and other revenue recognized were not material.
Petra
As a result of our acquisition of Petra, we are required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3Kα inhibitor. Our more significant, near term milestones include a development milestone of approximately $205 million in 2022 contingent upon initiation of its Phase I trial and a further development milestone of approximately $164 million in 2023 contingent upon achieving clinical proof of concept.
20
Note 5: Asset Impairment, Restructuring, and Other Special Charges
The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below.
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Severance | $ | — | $ | 144.4 | $ | 11.5 | $ | 154.2 | |||||||||||||||
| Asset impairment (recovery) and other special charges | — | (43.0) | 200.1 | 7.1 | |||||||||||||||||||
| Total asset impairment, restructuring, and other special charges | $ | — | $ | 101.4 | $ | 211.6 | $ | 161.3 | |||||||||||||||
Asset impairment, restructuring, and other special charges recognized during the nine months ended September 30, 2021 were primarily related to an intangible asset impairment of $108.1 million resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail.
Severance costs recognized during the three and nine months ended September 30, 2020 were incurred as a result of actions taken worldwide to reduce our cost structure. Substantially all of the severance costs incurred during the three and nine months ended September 30, 2020 have been paid.
We recognized a net inventory impairment charge related to our COVID-19 antibodies of $435.1 million during the nine months ended September 30, 2021 in cost of sales in our consolidated condensed statements of operations. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.
Note 6: Financial Instruments
Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life science products account for a substantial portion of our trade receivables; collateral is generally not required. We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.
We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.
Our equity investments are accounted for using three different methods depending on the type of equity investment:
•Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense.
•For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Any change in recorded value is recorded in other-net, (income) expense.
•Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense.
We review equity investments other than public equity investments for indications of impairment and observable price changes on a regular basis.
21
Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive loss. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.
We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, British pound, and Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2021, we had outstanding foreign currency forward commitments to purchase 707.3 million U.S. dollars and sell 604.5 million euro, commitments to purchase 2.54 billion euro and sell 2.98 billion U.S. dollars, commitments to purchase 151.6 million U.S. dollars and sell 980.0 million Chinese yuan, commitments to purchase 144.7 million U.S. dollars and sell 16.13 billion Japanese yen, and commitments to purchase 155.5 million British pounds and sell 212.6 million U.S. dollars, which all have settlement dates within 180 days.
Foreign currency exchange risk is also managed through the use of foreign currency debt and cross-currency interest rate swaps. Our foreign currency-denominated notes had carrying amounts of $8.08 billion and $6.02 billion as of September 30, 2021 and December 31, 2020, respectively, of which $5.95 billion and $4.50 billion have been designated as, and are effective as, economic hedges of net investments in certain of our foreign operations as of September 30, 2021 and December 31, 2020, respectively. At September 30, 2021, we had outstanding cross-currency swaps with notional amounts of $2.69 billion swapping U.S. dollars to euro and $1.00 billion swapping Swiss francs to U.S. dollars which have settlement dates ranging through 2028. Our cross-currency interest rate swaps, for which a majority convert a portion of our U.S. dollar-denominated fixed-rate debt to foreign-denominated fixed-rate debt, have also been designated as, and are effective as, economic hedges of net investments.
In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.
Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statements of cash flows. At September 30, 2021, substantially all of our total long-term debt is at a fixed rate. We have converted approximately 12 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.
We also may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. The change in fair value of these instruments is recorded as part of other comprehensive income (loss), and upon completion of a debt issuance and termination of the swap, is amortized to interest expense over the life of the underlying debt. As of September 30, 2021, the total notional amounts of forward-starting interest rate contracts in designated cash flow hedging instruments were $1.75 billion, which have settlement dates ranging between 2023 and 2025.
22
In September 2021, we issued euro-denominated notes consisting of €600.0 million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering will be used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives.
In September 2021, we issued euro-denominated notes consisting of €500.0 million of 1.125 percent fixed-rate notes due in September 2051 and €700.0 million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of £250.0 million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91 billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50 billion, resulting in a debt extinguishment loss of $405.2 million. This loss was included in other-net, (income) expense in our consolidated statement of operations during the three and nine months ended September 30, 2021. The $1.50 billion principal amount of higher interest rate U.S. dollar-denominated notes that were redeemed primarily included $541.8 million of 3.95 percent notes due 2049, $408.7 million of 4.15 percent notes due 2059, and $219.4 million of 3.375 percent notes due 2029. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes.
The Effect of Risk-Management Instruments on the Consolidated Condensed Statements of Operations
The following effects of risk-management instruments were recognized in other–net, (income) expense:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Fair value hedges: | |||||||||||||||||||||||
| Effect from hedged fixed-rate debt | $ | (10.1) | $ | (14.0) | $ | (60.5) | $ | 110.4 | |||||||||||||||
| Effect from interest rate contracts | 10.1 | 14.0 | 60.5 | (110.4) | |||||||||||||||||||
| Cash flow hedges: | |||||||||||||||||||||||
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss | 4.2 | 4.1 | 12.5 | 12.3 | |||||||||||||||||||
Cross-currency interest rate swaps | 10.0 | (30.2) | 58.1 | (54.6) | |||||||||||||||||||
Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments | 50.8 | (54.2) | 110.6 | (82.8) | |||||||||||||||||||
| Total | $ | 65.0 | $ | (80.3) | $ | 181.2 | $ | (125.1) | |||||||||||||||
During the three and nine months ended September 30, 2021 and 2020, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.
23
The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss)
The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Net investment hedges: | |||||||||||||||||||||||
| Foreign currency-denominated notes | $ | 119.0 | $ | (181.1) | $ | 268.8 | $ | (186.0) | |||||||||||||||
| Cross-currency interest rate swaps | 66.7 | (110.4) | 170.8 | (55.4) | |||||||||||||||||||
| Cash flow hedges: | |||||||||||||||||||||||
| Forward-starting interest rate swaps | 19.4 | 99.6 | 149.3 | (231.9) | |||||||||||||||||||
| Cross-currency interest rate swaps | 3.1 | 6.6 | 22.5 | (58.3) | |||||||||||||||||||
During the next 12 months, we expect to reclassify $16.4 million of pretax net losses on cash flow hedges from accumulated other comprehensive loss to other–net, (income) expense. During the three and nine months ended September 30, 2021 and 2020, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.
24
Fair Value of Financial Instruments
The following tables summarize certain fair value information at September 30, 2021 and December 31, 2020 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:
| Fair Value Measurements Using | |||||||||||||||||||||||||||||||||||
| Carrying Amount | Cost (1) | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Fair Value | ||||||||||||||||||||||||||||||
| September 30, 2021 | |||||||||||||||||||||||||||||||||||
| Cash equivalents | $ | 2,373.8 | $ | 2,373.8 | $ | 2,373.8 | $ | — | $ | — | $ | 2,373.8 | |||||||||||||||||||||||
| Short-term investments: | |||||||||||||||||||||||||||||||||||
| U.S. government and agency securities | $ | 11.3 | $ | 11.1 | $ | 11.3 | $ | — | $ | — | $ | 11.3 | |||||||||||||||||||||||
| Corporate debt securities | 6.8 | 6.7 | — | 6.8 | — | 6.8 | |||||||||||||||||||||||||||||
| Mortgage-backed securities | 0.2 | 0.2 | — | 0.2 | — | 0.2 | |||||||||||||||||||||||||||||
| Asset-backed securities | 3.3 | 3.2 | — | 3.3 | — | 3.3 | |||||||||||||||||||||||||||||
| Other securities | 15.5 | 15.5 | 6.6 | — | 8.9 | 15.5 | |||||||||||||||||||||||||||||
| Short-term investments | $ | 37.1 | |||||||||||||||||||||||||||||||||
| Noncurrent investments: | |||||||||||||||||||||||||||||||||||
| U.S. government and agency securities | $ | 129.9 | $ | 129.0 | $ | 129.9 | $ | — | $ | — | $ | 129.9 | |||||||||||||||||||||||
| Corporate debt securities | 219.7 | 215.0 | — | 219.7 | — | 219.7 | |||||||||||||||||||||||||||||
| Mortgage-backed securities | 110.7 | 107.9 | — | 110.7 | — | 110.7 | |||||||||||||||||||||||||||||
| Asset-backed securities | 19.7 | 19.6 | — | 19.7 | — | 19.7 | |||||||||||||||||||||||||||||
| Other securities | 105.6 | 21.6 | — | — | 105.6 | 105.6 | |||||||||||||||||||||||||||||
| Marketable equity securities | 1,482.8 | 420.5 | 1,482.8 | — | — | 1,482.8 | |||||||||||||||||||||||||||||
Equity investments without readily determinable fair values (2) | 556.3 | ||||||||||||||||||||||||||||||||||
Equity method investments (2) | 725.8 | ||||||||||||||||||||||||||||||||||
| Noncurrent investments | $ | 3,350.5 | |||||||||||||||||||||||||||||||||
| December 31, 2020 | |||||||||||||||||||||||||||||||||||
| Cash equivalents | $ | 2,097.9 | $ | 2,097.9 | $ | 2,097.9 | $ | — | $ | — | $ | 2,097.9 | |||||||||||||||||||||||
| Short-term investments: | |||||||||||||||||||||||||||||||||||
| U.S. government and agency securities | $ | 9.9 | $ | 9.9 | $ | 9.9 | $ | — | $ | — | $ | 9.9 | |||||||||||||||||||||||
| Corporate debt securities | 2.8 | 2.8 | — | 2.8 | — | 2.8 | |||||||||||||||||||||||||||||
| Asset-backed securities | 1.2 | 1.2 | — | 1.2 | — | 1.2 | |||||||||||||||||||||||||||||
| Other securities | 10.3 | 10.3 | — | — | 10.3 | 10.3 | |||||||||||||||||||||||||||||
| Short-term investments | $ | 24.2 | |||||||||||||||||||||||||||||||||
| Noncurrent investments: | |||||||||||||||||||||||||||||||||||
| U.S. government and agency securities | $ | 78.7 | $ | 74.3 | $ | 78.7 | $ | — | $ | — | $ | 78.7 | |||||||||||||||||||||||
| Corporate debt securities | 137.0 | 126.8 | — | 137.0 | — | 137.0 | |||||||||||||||||||||||||||||
| Mortgage-backed securities | 106.4 | 101.4 | — | 106.4 | — | 106.4 | |||||||||||||||||||||||||||||
| Asset-backed securities | 24.3 | 23.7 | — | 24.3 | — | 24.3 | |||||||||||||||||||||||||||||
| Other securities | 110.5 | 31.8 | — | — | 110.5 | 110.5 | |||||||||||||||||||||||||||||
| Marketable equity securities | 1,664.2 | 311.6 | 1,664.2 | — | — | 1,664.2 | |||||||||||||||||||||||||||||
Equity investments without readily determinable fair values (2) | 373.9 | ||||||||||||||||||||||||||||||||||
Equity method investments (2) | 471.8 | ||||||||||||||||||||||||||||||||||
| Noncurrent investments | $ | 2,966.8 | |||||||||||||||||||||||||||||||||
(1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.
(2) Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.
25
| Fair Value Measurements Using | |||||||||||||||||||||||||||||
| Carrying Amount | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Fair Value | |||||||||||||||||||||||||
| Long-term debt, including current portion | |||||||||||||||||||||||||||||
| September 30, 2021 | $ | (17,085.4) | $ | — | $ | (18,354.9) | $ | — | $ | (18,354.9) | |||||||||||||||||||
| December 31, 2020 | (16,595.3) | — | (19,038.9) | — | (19,038.9) | ||||||||||||||||||||||||
26
| Fair Value Measurements Using | |||||||||||||||||||||||||||||
| Carrying Amount | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Fair Value | |||||||||||||||||||||||||
| September 30, 2021 | |||||||||||||||||||||||||||||
| Risk-management instruments: | |||||||||||||||||||||||||||||
| Interest rate contracts designated as fair value hedges: | |||||||||||||||||||||||||||||
| Other receivables | $ | 8.5 | $ | — | $ | 8.5 | $ | — | $ | 8.5 | |||||||||||||||||||
| Other noncurrent assets | 87.2 | $ | — | 87.2 | $ | — | 87.2 | ||||||||||||||||||||||
| Other noncurrent liabilities | (2.2) | — | (2.2) | — | (2.2) | ||||||||||||||||||||||||
| Interest rate contracts designated as cash flow hedges: | |||||||||||||||||||||||||||||
| Other noncurrent assets | 77.3 | — | 77.3 | — | 77.3 | ||||||||||||||||||||||||
| Cross-currency interest rate contracts designated as net investment hedges: | |||||||||||||||||||||||||||||
| Other receivables | 18.7 | — | 18.7 | — | 18.7 | ||||||||||||||||||||||||
| Other noncurrent assets | 38.7 | — | 38.7 | — | 38.7 | ||||||||||||||||||||||||
| Other current liabilities | (17.0) | — | (17.0) | — | (17.0) | ||||||||||||||||||||||||
| Other noncurrent liabilities | (9.5) | — | (9.5) | — | (9.5) | ||||||||||||||||||||||||
| Cross-currency interest rate contracts designated as cash flow hedges: | |||||||||||||||||||||||||||||
| Other noncurrent assets | 10.8 | — | 10.8 | — | 10.8 | ||||||||||||||||||||||||
| Other noncurrent liabilities | (23.0) | — | (23.0) | — | (23.0) | ||||||||||||||||||||||||
| Foreign exchange contracts not designated as hedging instruments: | |||||||||||||||||||||||||||||
| Other receivables | 5.5 | — | 5.5 | — | 5.5 | ||||||||||||||||||||||||
| Other current liabilities | (25.7) | — | (25.7) | — | (25.7) | ||||||||||||||||||||||||
| Contingent consideration liability: | |||||||||||||||||||||||||||||
| Other noncurrent liabilities | (70.7) | — | — | (70.7) | (70.7) | ||||||||||||||||||||||||
| December 31, 2020 | |||||||||||||||||||||||||||||
| Risk-management instruments: | |||||||||||||||||||||||||||||
| Interest rate contracts designated as fair value hedges: | |||||||||||||||||||||||||||||
| Other noncurrent assets | 158.9 | — | 158.9 | — | 158.9 | ||||||||||||||||||||||||
| Interest rate contracts designated as cash flow hedges: | |||||||||||||||||||||||||||||
| Other noncurrent assets | 38.1 | — | 38.1 | — | 38.1 | ||||||||||||||||||||||||
| Other noncurrent liabilities | (97.8) | — | (97.8) | — | (97.8) | ||||||||||||||||||||||||
| Cross-currency interest rate contracts designated as net investment hedges: | |||||||||||||||||||||||||||||
| Other current liabilities | (92.6) | — | (92.6) | — | (92.6) | ||||||||||||||||||||||||
| Other noncurrent liabilities | (97.2) | — | (97.2) | — | (97.2) | ||||||||||||||||||||||||
| Cross-currency interest rate contracts designated as cash flow hedges: | |||||||||||||||||||||||||||||
| Other noncurrent assets | 34.4 | — | 34.4 | — | 34.4 | ||||||||||||||||||||||||
| Other noncurrent liabilities | (2.9) | — | (2.9) | — | (2.9) | ||||||||||||||||||||||||
| Foreign exchange contracts not designated as hedging instruments: | |||||||||||||||||||||||||||||
| Other receivables | 41.1 | — | 41.1 | — | 41.1 | ||||||||||||||||||||||||
| Other current liabilities | (15.2) | — | (15.2) | — | (15.2) | ||||||||||||||||||||||||
27
Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.
We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions. Fair values are not readily available for certain equity investments measured under the measurement alternative. As of September 30, 2021, we had approximately $781 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years.
Contingent consideration liability relates to our liability arising in connection with the CVR issued as a result of the Prevail acquisition. The fair value of the CVR liability was estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payment associated with the first potential regulatory approval of a Prevail compound in the applicable countries based on probabilities of technical success, timing of the potential approval events for the compounds, and an estimated discount rate. See Note 3 for additional information related to the CVR arrangement.
The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September 30, 2021:
| Maturities by Period | |||||||||||||||||||||||||||||
| Total | Less Than 1 Year | 1-5 Years | 6-10 Years | More Than 10 Years | |||||||||||||||||||||||||
| Fair value of debt securities | $ | 501.6 | $ | 21.6 | $ | 157.8 | $ | 153.4 | $ | 168.8 | |||||||||||||||||||
The net gains (losses) recognized in our consolidated condensed statements of operations for equity securities were $(246.8) million and $270.1 million for the three and nine months ended September 30, 2021, respectively, and $141.7 million and $905.1 million for the three and nine months ended September 30, 2020, respectively. The net gains/losses recognized during the three and nine months ended September 30, 2021 and 2020 on equity securities sold during the respective periods were not material.
We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near term prospects of the issuer, general market conditions, and industry specific factors. Adjustments recorded during the three and nine months ended September 30, 2021 and 2020 were not material.
A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:
| September 30, 2021 | December 31, 2020 | ||||||||||
| Unrealized gross gains | $ | 12.5 | $ | 20.9 | |||||||
| Unrealized gross losses | 4.0 | 0.5 | |||||||||
| Fair value of securities in an unrealized gain position | 293.4 | 348.9 | |||||||||
| Fair value of securities in an unrealized loss position | 208.1 | 11.4 | |||||||||
We periodically assess our investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. Impairment and credit losses related to available-for-sale securities were not material for the three and nine months ended September 30, 2021 and 2020.
28
As of September 30, 2021, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions. Approximately 97 percent of the fixed-rate debt securities in a loss position are investment-grade debt securities. As of September 30, 2021, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities.
Activity related to our available-for-sale securities was as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Proceeds from sales | $ | 49.6 | $ | 14.0 | $ | 137.3 | $ | 246.8 | |||||||||||||||
| Realized gross gains on sales | 0.4 | 0.4 | 2.2 | 4.0 | |||||||||||||||||||
| Realized gross losses on sales | 0.3 | 0.2 | 1.1 | 8.2 | |||||||||||||||||||
Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.
Accounts Receivable Factoring Arrangements
We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and, risk related to, the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $617.4 million and $754.9 million of accounts receivable as of September 30, 2021 and December 31, 2020, respectively, under these factoring arrangements. The costs of factoring such accounts receivable on our consolidated condensed results of operations for the three and nine months ended September 30, 2021 and 2020 were not material.
Note 7: Income Taxes
The effective tax rate was 10.9 percent for the three months ended September 30, 2021, compared with 15.9 percent for the three months ended September 30, 2020. The lower effective tax rate for the three months ended September 30, 2021 was primarily due to the income tax impact of a debt extinguishment loss and unfavorable mark-to-market adjustments on investments in equity securities, partially offset by a lower net discrete tax benefit compared to the three months ended September 30, 2020. The effective tax rate was 10.7 percent for the nine months ended September 30, 2021, compared with 14.4 percent for the nine months ended September 30, 2020. The lower effective tax rate for the nine months ended September 30, 2021 was primarily due to the income tax impacts of a net inventory impairment charge related to our COVID-19 antibodies and a debt extinguishment loss, as well as higher acquired IPR&D charges and lower favorable mark-to-market adjustments on investments in equity securities compared to the nine months ended September 30, 2020, partially offset by a lower net discrete tax benefit compared to the nine months ended September 30, 2020.
The U.S. examination of tax years 2016-2018 began in the fourth quarter of 2019 and remains ongoing. The resolution of this audit period will likely extend beyond the next 12 months.
29
Note 8: Retirement Benefits
Net pension and retiree health benefit (income) cost included the following components:
| Defined Benefit Pension Plans | |||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Components of net periodic benefit cost: | |||||||||||||||||||||||
| Service cost | $ | 92.5 | $ | 81.7 | $ | 277.8 | $ | 243.4 | |||||||||||||||
| Interest cost | 84.5 | 106.6 | 253.6 | 319.0 | |||||||||||||||||||
| Expected return on plan assets | (237.5) | (229.5) | (712.7) | (671.4) | |||||||||||||||||||
| Amortization of prior service cost | 1.0 | 1.1 | 3.2 | 3.2 | |||||||||||||||||||
| Recognized actuarial loss | 121.9 | 58.4 | 366.3 | 286.5 | |||||||||||||||||||
| Net periodic benefit cost | $ | 62.4 | $ | 18.3 | $ | 188.2 | $ | 180.7 | |||||||||||||||
| Retiree Health Benefit Plans | |||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Components of net periodic benefit income: | |||||||||||||||||||||||
| Service cost | $ | 12.4 | $ | 10.2 | $ | 37.0 | $ | 30.6 | |||||||||||||||
| Interest cost | 8.1 | 10.9 | 24.4 | 32.8 | |||||||||||||||||||
| Expected return on plan assets | (36.5) | (40.3) | (109.6) | (115.1) | |||||||||||||||||||
| Amortization of prior service benefit | (14.9) | (21.9) | (44.7) | (51.6) | |||||||||||||||||||
| Recognized actuarial loss | 0.8 | 0.7 | 2.4 | 2.1 | |||||||||||||||||||
| Net periodic benefit income | $ | (30.1) | $ | (40.4) | $ | (90.5) | $ | (101.2) | |||||||||||||||
Note 9: Contingencies
We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that we believe could become significant or material are described below.
We believe the legal proceedings in which we are named as defendants are without merit and we are defending against them vigorously. It is not possible to determine the final outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.
Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated condensed balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.
30
Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently and previously marketed products.
Patent Litigation
Alimta Patent Litigation
U.S. Patent Litigation
Alimta (pemetrexed) is protected by a vitamin regimen patent until November 2021, plus pediatric exclusivity through May 2022.
In December 2019, we settled a lawsuit we filed against Eagle Pharmaceuticals, Inc. (Eagle) in response to its application to market a product using an alternative form of pemetrexed. Per the settlement agreement, Eagle has a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022.
European Patent Litigation
In Europe, Alimta was protected by the vitamin regimen patent through June 2021. Despite the recent patent expiration, a number of legal proceedings that were initiated prior to expiration are ongoing.
Emgality Patent Litigation
In September 2018, we were named as a defendant in litigation filed by Teva Pharmaceuticals International GMBH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) in the U.S. District Court for the District of Massachusetts seeking a ruling that various claims in nine different Teva patents would be infringed by our launch and continued sales of Emgality for the prevention of migraine in adults. Trial is expected in March 2022. In June 2021, we were named as a defendant in a second litigation filed by Teva in the U.S. District Court for the District of Massachusetts seeking a ruling that two of Teva’s patents, which are directed toward use of the active ingredient in Emgality to treat migraine, would be infringed by our continued sales of Emgality.
Separately, the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) granted our request to initiate an inter partes review (IPR) to reexamine the validity of the nine Teva patents asserted against us in the litigation. In February 2020, the PTAB ruled in our favor and found that the claims asserted against us in six of Teva's nine patents were invalid. In March 2020, the PTAB ruled against us on the remaining three Teva patents, finding that we failed to show that the remaining three patents were unpatentable based on the subset of invalidity arguments available in an IPR proceeding. In April 2020, we appealed the PTAB’s March 2020 ruling, and Teva appealed the PTAB’s February 2020 ruling to the U.S. Court of Appeals for the Federal Circuit. In August 2021, the appeals court affirmed all nine of the PTAB's decisions. Neither Lilly nor Teva appealed the rulings and accordingly those decisions are final, and the parties have agreed to a stipulation which removes the six invalidated patents from the district court litigation. This IPR matter is now closed.
Jardiance Patent Litigation
In November 2018, Boehringer Ingelheim (BI), our partner in marketing and development of Jardiance, initiated U.S. patent litigation in the U.S. District Court of Delaware alleging infringement arising from submissions of Abbreviated New Drug Applications (ANDA) by a number of generic companies seeking approval to market generic versions of Jardiance, Glyxambi, and Synjardy in accordance with the procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Particularly with respect to Jardiance, the generic companies' ANDAs seek approval to market generic versions of Jardiance prior to the expiration of the relevant patents, and allege that certain patents, including in some allegations the compound patent, are invalid or would not be infringed. We are not a party to this litigation. This litigation has been stayed.
Taltz Patent Litigation
In April 2021, we petitioned the High Court of Ireland to declare invalid the patent that Novartis Pharma AG (Novartis) purchased from Genentech, Inc. in 2020. Novartis responded by filing a claim against us alleging patent infringement related to our commercialization of Taltz and seeking damages for past infringement and an injunction against future infringement. This matter is ongoing.
31
In April 2021 and June 2021, Novartis petitioned the Court of Rome Intellectual Property Division and the Commercial Court of Vienna, respectively, in preliminary injunction infringement proceedings against us related to our commercialization of Taltz. In June 2021, the Court of Rome Intellectual Property Division dismissed Novartis’ preliminary injunction action. Novartis has appealed the ruling and in October 2021 the panel hearing Novartis' appeal appointed a technical expert to assess the merits of the case. Both matters are ongoing.
Zyprexa Canada Patent Litigation
Beginning in the mid-2000’s, several generic companies in Canada challenged the validity of our Zyprexa compound patent. In 2012, the Canadian Federal Court of Appeals denied our appeal of a lower court's decision that certain patent claims were invalid for lack of utility. In 2013, Apotex Inc. and Apotex Pharmachem Inc. (collectively, Apotex) brought claims against us in the Ontario Superior Court of Justice at Toronto for damages related to our enforcement of the Zyprexa compound patent under Canadian regulations governing patented drugs. Apotex seeks compensation based on novel legal theories under the Statute of Monopolies, Trade-Mark Act, and common law. In March 2021, the Ontario Superior Court granted our motion for summary judgement, thereby dismissing Apotex’s case. Apotex appealed that ruling to the Court of Appeal for Ontario in April 2021 and a hearing is scheduled for February 2022.
Product Liability Litigation
Actos® Product Liability
We are named along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda) as a defendant in four purported product liability class actions in Canada related to Actos, which we commercialized with Takeda in Canada until 2009, including one in Ontario filed December 2011 (Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al.), one in Quebec filed July 2012 (Whyte et al. v. Eli Lilly et al.), one in Saskatchewan filed November 2017 (Weiler v. Takeda Canada Inc. et al.), and one in Alberta filed January 2013 (Epp v. Takeda Canada Inc. et al.). In general, plaintiffs in these actions alleged that Actos caused or contributed to their bladder cancer. An agreement to settle these actions became effective in May 2021, and the settlement claims administration process is ongoing. The lawsuits have been dismissed or discontinued.
Byetta® Product Liability
We are named as a defendant in approximately 570 Byetta product liability lawsuits in the U.S. which were initiated in March 2009 and involve approximately 805 plaintiffs. Approximately 55 of these lawsuits, covering about 285 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 515 of the lawsuits, covering about 515 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation (MDL) in the U.S. District Court for the Southern District of California. Two lawsuits, representing approximately two plaintiffs, have also been filed in various state courts. Approximately 565 of the lawsuits, involving approximately 800 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer); while six plaintiffs allege Byetta caused or contributed to pancreatitis. In addition, one case alleges that Byetta caused or contributed to ampullary cancer. The federal and state trial courts granted summary judgment in favor of us and our co-defendants on the claims alleging pancreatic cancer. The plaintiffs appealed those rulings.
In November 2017, the U.S. Court of Appeals for the Ninth Circuit reversed the U.S. District Court for the Southern District of California's grant of summary judgment in the MDL based on that court's discovery rulings and remanded the cases back to the U.S. District Court for further proceedings. In March 2021, the U.S. District Court granted summary judgment for the defendants. In April 2021, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit, but we have now been dismissed from that appeal. Certain plaintiffs have agreed to dismiss their lawsuits in exchange for a waiver of costs, and individual plaintiffs have begun dismissing their claims based upon this agreement. Approximately 160 of the MDL pancreatic lawsuits have been dismissed as of October 2021. In the state court actions, in November 2018, the California Court of Appeal reversed the Los Angeles County Superior Court of California’s grant of summary judgment based on that court's discovery rulings and remanded for further proceedings. In April 2021, the Los Angeles County Superior Court of California granted summary judgment for the defendants and the parties await entry of the order of judgment.
We are aware of approximately 20 additional claimants who have not yet filed suit. These additional claims allege damages for pancreatic cancer or thyroid cancer.
32
Cialis Product Liability
We are named as a defendant in approximately 350 Cialis product liability lawsuits in the U.S. which were first initiated in August 2015. These cases, many of which were originally filed in various federal courts, contain allegations that Cialis caused or contributed to the plaintiffs' cancer (melanoma). In December 2016, the Judicial Panel on Multidistrict Litigation (JPML) granted the plaintiffs' petition to have filed cases and an unspecified number of future cases coordinated into a federal multidistrict litigation (MDL) in the U.S. District Court for the Northern District of California, alongside an existing coordinated proceeding involving Viagra®. The JPML ordered the transfer of the existing cases to the now-renamed MDL In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation. In April 2020, the MDL court granted summary judgment to the defendants on all of the claims brought against them by the plaintiffs. In May 2020, plaintiffs filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. The plaintiffs’ appeal was administratively closed until August 2021 pending completion of a procedure to resolve the claims in this litigation. The court has entered an extension until February 2022 to finalize resolution of all claims.
Jardiance Product Liability
First initiated in January 2019, we and Boehringer Ingelheim Pharmaceuticals, Inc., a subsidiary of BI, have been named as a defendant in approximately 95 product liability lawsuits in the U.S., mostly in Stamford Superior Court in Connecticut, alleging that Jardiance caused or contributed to plaintiffs’ Fournier’s gangrene. Our agreement with BI calls for BI to defend and indemnify us against any damages, costs, expenses, and certain other losses with respect to product liability claims in accordance with the terms of the agreement. All pending cases have been paused to allow for settlement negotiations.
Environmental Proceedings
Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as "Superfund," we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites. Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.
Other Matters
340B Litigation and Investigations
We are the plaintiff in a lawsuit filed in January 2021 in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA. The lawsuit challenges the HHS's December 30, 2020 advisory opinion stating that drug manufacturers are required to deliver discounts under the 340B program to all contract pharmacies. We seek a declaratory judgment that the defendants violated the Administrative Procedures Act and the U.S. Constitution, a preliminary injunction enjoining implementation of the administrative dispute resolution process created by defendants and, with it, their application of the advisory opinion, and other related relief. In March 2021, the court entered an order preliminarily enjoining the government’s enforcement of the administrative dispute resolution process against us. In May 2021, HRSA notified us that it determined that our policy was contrary to the 340B statute. In response, in May 2021, we filed a motion for preliminary injunction and temporary restraining order requesting that the U.S. District Court for the Southern District of Indiana enjoin defendants from taking any action against us relating to the 340B drug pricing program until after the court issues a final judgment on the aforementioned litigation. In May 2021, the court denied our motion for a temporary restraining order but deferred resolution of our motion for preliminary injunction. In June 2021, the defendants withdrew the HHS December 30, 2020 advisory opinion. In July 2021, the court held oral argument on the parties’ cross motions for summary judgment, the defendants’ motion to dismiss, and our motion for preliminary injunction related to HRSA’s May 2021 enforcement letter. This matter is ongoing.
In January 2021, we, along with other pharmaceutical manufacturers, were named as a defendant in a petition currently pending before the HHS Administrative Dispute Resolution Panel. Petitioner seeks declaratory and other injunctive relief related to the 340B program. As described above, the U.S. District Court for the Southern District of Indiana has entered a preliminary injunction enjoining the government’s enforcement of this administrative dispute resolution process against us.
In July 2021, we, along with Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP, were named as a defendant in a purported class action lawsuit filed in the U.S. District Court for the Western District of New York by Mosaic Health, Inc. alleging antitrust and unjust enrichment claims related to the defendants' 340B distribution programs.
33
We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program. We are cooperating with this subpoena.
Branchburg Manufacturing Facility
In May 2021, we received a subpoena from the United States Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.
Brazil Litigation – Cosmopolis Facility
Labor Attorney Litigation
First initiated in 2008, our subsidiary in Brazil, Eli Lilly do Brasil Limitada (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for the 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly Brasil manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. In May 2014, the labor court judge ruled against Lilly Brasil, ordering it to undertake several actions of unspecified financial impact, including paying lifetime health coverage for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. We appealed this decision. In July 2018, the appeals court affirmed the labor court's ruling with a liquidated award of 300 million Brazilian real (for moral damages, donation of equipment, and creation of a foundation) which, adjusted for inflation and interest using the current Central Bank of Brazil's special system of clearance and custody rate (SELIC), is approximately 950 million Brazilian real (approximately $175 million as of September 30, 2021). The appeals court restricted the broad health coverage awarded by the labor court to health problems that claimants could show arose from exposure to the alleged contamination. In August 2019, Lilly Brasil filed an appeal to the superior labor court. In September 2019, the appeals court stayed a number of elements of its prior decision, including the obligation to provide health coverage for contractors, their children, and children of employees who worked at the Cosmopolis facility, pending the determination of Lilly Brasil’s appeal to the superior labor court. The cost of any such health coverage has not been determined. In June 2021, the appeals court published its decision on the admissibility of Lilly Brasil’s appeal, admitting the majority of the elements of the appeal to proceed; elements not proceeding are subject to an interlocutory appeal to the appeals court filed in June 2021.
In June 2019, the Labor Attorney filed an application in the labor court for enforcement of the healthcare coverage granted by the appeals court in its July 2018 ruling and requested restrictions on Lilly Brasil’s assets in Brazil. In July 2019, the labor court issued a ruling requiring either a freeze of Lilly Brasil’s immovable property or, alternatively, a security deposit or lien of 500 million Brazilian real. Lilly Brasil filed a writ of mandamus challenging this ruling, but the court has stayed its decision on this writ and instead directed the parties to attend conciliation hearings, a process that concluded unsuccessfully in September 2020. Consequently, the partial stay of the proceedings relating to Lilly Brasil's application to appeal in the main proceedings has been lifted and in June 2021, the court reduced the security deposit or lien to 100 million Brazilian real from the 500 million Brazilian real referred to above. In addition, the Labor Attorney's application for preliminary enforcement of the July 2018 healthcare coverage ruling was granted. As the conciliation hearings have been unsuccessful, we have filed a brief to strike the Labor Attorney’s application to enforce the previous healthcare coverage. Lilly Brasil is currently awaiting a determination as to whether its application seeking leave to appeal to the superior labor court has been successful.
Individual Former Employee Litigation
We are also named in approximately 30 lawsuits filed in the same labor court by individual former employees making similar claims. These lawsuits are each at various stages in the litigation process, with judgments being handed down in approximately half of the lawsuits, nearly all of which are on appeal in the labor courts.
China NDRC Antitrust Matter
The competition authority in China has investigated our distributor pricing practices in China in connection with a broader inquiry into pharmaceutical industry pricing. We have cooperated with this investigation.
Eastern District of Pennsylvania Pricing (Average Manufacturer Price) Inquiry
In November 2014, we, along with another pharmaceutical manufacturer, were named as co-defendants in United States et al. ex rel. Streck v. Takeda Pharm. Am., Inc., et al., which was filed in November 2014 and unsealed in the U.S. District Court for the Northern District of Illinois. The complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices. Trial is scheduled for April 2022.
34
Health Choice Alliance
We are named as a defendant in a lawsuit filed in June 2017 in the U.S. District Court for the Eastern District of Texas seeking damages under the federal anti-kickback statute and state and federal false claims acts for certain patient support programs related to our products Humalog, Humulin, and Forteo. In September 2019, the U.S. District Court granted the U.S. Department of Justice’s motion to dismiss the relator’s second amended complaint. In January 2020, the relator appealed the District Court’s dismissal to the U.S. Court of Appeals for the Fifth Circuit. In July 2021, the U.S. Court of Appeals for the Fifth Circuit affirmed the dismissal of the lawsuit. We are also named as a defendant in two similar lawsuits filed in Texas and New Jersey state courts in October 2019 seeking damages under the Texas Medicaid Fraud Prevention Act and New Jersey Medicaid False Claims Act, respectively. In November 2020, the Texas state court action was stayed pending a final determination with respect to the aforementioned federal lawsuit. In April 2021, the New Jersey state court action was dismissed with prejudice and in June 2021, the relator filed a notice of appeal to the Appellate Division of the New Jersey Superior Court, appealing the state court’s decision.
Pricing Litigation, Investigations, and Inquiries
Litigation
In December 2017, we, along with Sanofi and Novo Nordisk were named as defendants in a consolidated purported class action lawsuit, In re. Insulin Pricing Litigation, in the U.S. District Court for the District of New Jersey relating to insulin pricing seeking damages under various state consumer protection laws and the Federal Racketeer Influenced and Corrupt Organization Act (federal RICO Act). Separately, in February 2018, we, along with Sanofi and Novo Nordisk, were named as defendants in MSP Recovery Claims, Series, LLC et al. v. Sanofi Aventis U.S. LLC et al., in the same court, seeking damages under various state consumer protection laws, common law fraud, unjust enrichment, and the federal RICO Act. In both In re. Insulin Pricing Litigation and the MSP Recovery Claims litigation, the court dismissed claims under the federal RICO Act and certain state laws. In April 2021, the plaintiffs in In re. Insulin Pricing Litigation amended their complaint to allege additional state law claims for civil conspiracy and violations of state RICO statutes. Also, we, along with Sanofi, Novo Nordisk, CVS, Express Scripts, and Optum, have been sued in a purported class action, FWK Holdings, LLC v. Novo Nordisk Inc., et al., filed in the same court in November 2020, for alleged violations of the federal RICO Act as well as the New Jersey RICO Act and antitrust law. That same group of defendants, along with Medco Health and United Health Group, also have been sued in other purported class actions in the same court, Rochester Drug Co-Operative Inc. v. Eli Lilly & Co. et al. and Value Drug Co. v. Eli Lilly & Co. et al. both initiated in March 2020, for alleged violations of the federal RICO Act. In September 2020, the U.S. District Court for the District of New Jersey granted plaintiffs’ motion to consolidate FWK Holdings, LLC v. Novo Nordisk Inc., et al., Rochester Drug Co-Operative Inc. v. Eli Lilly & Co. et al., and Value Drug Co. v. Eli Lilly & Co. et al. In July 2021, the U.S. District Court for the District of New Jersey dismissed the three antitrust claims alleged by plaintiffs in the consolidated litigation and denied dismissal of the RICO claims.
In October 2018, the Minnesota Attorney General’s Office initiated litigation against us, Sanofi, and Novo Nordisk, State of Minnesota v. Sanofi-Aventis U.S. LLC et al., in the U.S. District Court for the District of New Jersey, alleging unjust enrichment, violations of various Minnesota state consumer protection laws, and the federal RICO Act. In March 2021, the U.S. District Court for the District of New Jersey dismissed with prejudice the Minnesota Attorney General’s federal RICO claims and false advertising claims under state law; the consumer fraud and other related state law claims remain ongoing. Additionally, in May 2019, the Kentucky Attorney General’s Office filed a complaint against us, Sanofi, and Novo Nordisk, Commonwealth of Kentucky v. Novo Nordisk, Inc. et al., in Kentucky state court, alleging violations of the Kentucky consumer protection law, false advertising, and unjust enrichment. In November 2019, Harris County in Texas initiated litigation against us, Sanofi, Novo Nordisk, Express Scripts, CVS, Optum, and Aetna, County of Harris Texas v. Eli Lilly & Co., et al., in federal court in the Southern District of Texas alleging violations of the federal RICO Act, the state deceptive trade practices-consumer protection act, and common law claims such as fraud, unjust enrichment, and civil conspiracy. Harris County also alleged violations of federal and state antitrust law, but voluntarily dismissed them. This lawsuit relates to our insulin products as well as Trulicity.
In June 2021, the City of Miami, Florida initiated litigation against us, Sanofi, Novo Nordisk, ESI, CVS/Caremark/Aetna, and Optum, asserting state law antitrust, common law fraud, money had and received, unjust enrichment, and civil conspiracy claims. In June 2021, the Mississippi Attorney General’s Office initiated litigation against us, Sanofi, Novo Nordisk, Evernorth/ESI, CVS/Caremark, and United/Optum in the Hinds County, Mississippi Chancery Court, alleging state law consumer protection, unjust enrichment, and civil conspiracy claims.
35
Investigations, Subpoenas, and Inquiries
We received a subpoena from the New York and Vermont Attorney General Offices and civil investigative demands from the Washington, New Mexico, and Colorado Attorney General Offices relating to the pricing and sale of our insulin products. The Offices of the Attorney General in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada have requested information relating to the pricing and sale of our insulin products. We also received interrogatories and a subpoena from the California Attorney General's Office regarding our competition in the long-acting insulin market, which was subsequently withdrawn in June 2021.
We received a request in January 2019 from the House of Representatives’ Committee on Oversight and Reform seeking commercial information and business records related to the pricing of insulin products, among other issues. We also received requests from the Senate Finance Committee and the Senate Committee on Health, Education, Labor, and Pensions, and separate requests from the House Committee on Energy and Commerce majority and minority members. Those requests sought pricing and other commercial information regarding Lilly’s insulin products. In January 2021, the Senate Finance Committee released a report summarizing the findings of its investigation.
We are cooperating with all of these aforementioned investigations, subpoenas, and inquiries.
Research Corporation Technologies, Inc.
In April 2016, we were named as a defendant in litigation filed by Research Corporation Technologies, Inc. (RCT) in the U.S. District Court for the District of Arizona. RCT is seeking damages for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin. Both parties moved for summary judgment and a hearing on the motions took place in August 2021. In October 2021, the Court issued a summary judgment decision finding in favor of RCT on certain issues, including with respect to a disputed royalty. Potential damages payable under the litigation, if finally awarded after an appeal, could be material but are not currently reasonably estimable. We intend to appeal the summary judgment decision and related findings. A trial date has not been set.
36
Note 10: Other Comprehensive Income (Loss)
The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September 30, 2021 and 2020:
| (Amounts presented net of taxes) | Foreign Currency Translation Gains (Losses) | Unrealized Net Gains (Losses) on Securities | Defined Benefit Pension and Retiree Health Benefit Plans | Effective Portion of Cash Flow Hedges | Accumulated Other Comprehensive Loss | ||||||||||||||||||||||||
| Balance at July 1, 2021 | $ | (1,516.2) | $ | 9.1 | $ | (4,569.9) | $ | (210.1) | $ | (6,287.1) | |||||||||||||||||||
| Other comprehensive income (loss) before reclassifications | (8.0) | (2.4) | 18.6 | 16.8 | 25.0 | ||||||||||||||||||||||||
| Net amount reclassified from accumulated other comprehensive loss | — | 0.1 | 86.0 | 3.3 | 89.4 | ||||||||||||||||||||||||
| Net other comprehensive income (loss) | (8.0) | (2.3) | 104.6 | 20.1 | 114.4 | ||||||||||||||||||||||||
| Balance at September 30, 2021 | $ | (1,524.2) | $ | 6.8 | $ | (4,465.3) | $ | (190.0) | $ | (6,172.7) | |||||||||||||||||||
| (Amounts presented net of taxes) | Foreign Currency Translation Gains (Losses) | Unrealized Net Gains (Losses) on Securities | Defined Benefit Pension and Retiree Health Benefit Plans | Effective Portion of Cash Flow Hedges | Accumulated Other Comprehensive Loss | ||||||||||||||||||||||||
| Balance at July 1, 2020 | $ | (1,722.5) | $ | 15.1 | $ | (4,454.9) | $ | (520.6) | $ | (6,682.9) | |||||||||||||||||||
| Other comprehensive income (loss) before reclassifications | 30.3 | 0.8 | (19.6) | 82.9 | 94.4 | ||||||||||||||||||||||||
| Net amount reclassified from accumulated other comprehensive loss | — | (0.2) | 30.3 | 3.3 | 33.4 | ||||||||||||||||||||||||
| Net other comprehensive income (loss) | 30.3 | 0.6 | 10.7 | 86.2 | 127.8 | ||||||||||||||||||||||||
| Balance at September 30, 2020 | $ | (1,692.2) | $ | 15.7 | $ | (4,444.2) | $ | (434.4) | $ | (6,555.1) | |||||||||||||||||||
The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September 30, 2021 and 2020:
| (Amounts presented net of taxes) | Foreign Currency Translation Gains (Losses) | Unrealized Net Gains (Losses) on Securities | Defined Benefit Pension and Retiree Health Benefit Plans | Effective Portion of Cash Flow Hedges | Accumulated Other Comprehensive Loss | ||||||||||||||||||||||||
| Balance at January 1, 2021 | $ | (1,427.5) | $ | 14.8 | $ | (4,751.0) | $ | (332.7) | $ | (6,496.4) | |||||||||||||||||||
| Other comprehensive income (loss) before reclassifications | (96.7) | (8.8) | 27.2 | 132.8 | 54.5 | ||||||||||||||||||||||||
| Net amount reclassified from accumulated other comprehensive loss | — | 0.8 | 258.5 | 9.9 | 269.2 | ||||||||||||||||||||||||
| Net other comprehensive income (loss) | (96.7) | (8.0) | 285.7 | 142.7 | 323.7 | ||||||||||||||||||||||||
| Balance at September 30, 2021 | $ | (1,524.2) | $ | 6.8 | $ | (4,465.3) | $ | (190.0) | $ | (6,172.7) | |||||||||||||||||||
| (Amounts presented net of taxes) | Foreign Currency Translation Gains (Losses) | Unrealized Net Gains (Losses) on Securities | Defined Benefit Pension and Retiree Health Benefit Plans | Effective Portion of Cash Flow Hedges | Accumulated Other Comprehensive Loss | ||||||||||||||||||||||||
| Balance at January 1, 2020 | $ | (1,678.0) | $ | 4.9 | $ | (4,638.6) | $ | (211.9) | $ | (6,523.6) | |||||||||||||||||||
Other comprehensive income (loss) before reclassifications | (14.2) | 7.6 | 4.6 | (232.3) | (234.3) | ||||||||||||||||||||||||
Net amount reclassified from accumulated other comprehensive loss | — | 3.2 | 189.8 | 9.8 | 202.8 | ||||||||||||||||||||||||
Net other comprehensive income (loss) | (14.2) | 10.8 | 194.4 | (222.5) | (31.5) | ||||||||||||||||||||||||
| Balance at September 30, 2020 | $ | (1,692.2) | $ | 15.7 | $ | (4,444.2) | $ | (434.4) | $ | (6,555.1) | |||||||||||||||||||
37
The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| Tax benefit (expense) | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||
| Foreign currency translation gains/losses | $ | (39.0) | $ | 46.0 | $ | (92.3) | $ | 34.9 | |||||||||||||||
| Unrealized net gains/losses on securities | 0.8 | (0.2) | 3.8 | (3.0) | |||||||||||||||||||
| Defined benefit pension and retiree health benefit plans | (28.2) | 11.8 | (79.7) | (32.8) | |||||||||||||||||||
| Effective portion of cash flow hedges | (5.4) | (22.9) | (37.9) | 59.1 | |||||||||||||||||||
| Benefit (provision) for income taxes allocated to other comprehensive income (loss) items | $ | (71.8) | $ | 34.7 | $ | (206.1) | $ | 58.2 | |||||||||||||||
Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated condensed statements of operations.
Reclassifications out of accumulated other comprehensive loss were as follows:
| Details about Accumulated Other Comprehensive Loss Components | Three Months Ended September 30, | Nine Months Ended September 30, | Affected Line Item in the Consolidated Condensed Statements of Operations | ||||||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||||||||
Amortization of retirement benefit items: | |||||||||||||||||||||||||||||
Prior service benefits, net | $ | (13.9) | $ | (20.8) | $ | (41.5) | $ | (48.4) | Other–net, (income) expense | ||||||||||||||||||||
Actuarial losses, net | 122.7 | 59.1 | 368.7 | 288.6 | Other–net, (income) expense | ||||||||||||||||||||||||
| Total before tax | 108.8 | 38.3 | 327.2 | 240.2 | |||||||||||||||||||||||||
| Tax benefit | (22.8) | (8.0) | (68.7) | (50.4) | Income taxes | ||||||||||||||||||||||||
| Net of tax | 86.0 | 30.3 | 258.5 | 189.8 | |||||||||||||||||||||||||
Other, net of tax | 3.4 | 3.1 | 10.7 | 13.0 | Other–net, (income) expense | ||||||||||||||||||||||||
| Total reclassifications, net of tax | $ | 89.4 | $ | 33.4 | $ | 269.2 | $ | 202.8 | |||||||||||||||||||||
38
Note 11: Other–Net, (Income) Expense
Other–net, (income) expense consisted of the following:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
| Interest expense | $ | 83.6 | $ | 89.6 | $ | 258.4 | $ | 270.4 | |||||||||||||||
| Interest income | (7.0) | (5.8) | (18.0) | (27.2) | |||||||||||||||||||
| Net investment (gains) losses on equity securities (Note 6) | 246.8 | (141.7) | (270.1) | (905.1) | |||||||||||||||||||
| Retirement benefit plans | (72.6) | (114.0) | (217.1) | (194.5) | |||||||||||||||||||
| Debt extinguishment loss (Note 6) | 405.2 | — | 405.2 | — | |||||||||||||||||||
| Other (income) expense | (20.1) | 13.0 | (34.1) | 161.5 | |||||||||||||||||||
| Other–net, (income) expense | $ | 635.9 | $ | (158.9) | $ | 124.3 | $ | (694.9) | |||||||||||||||
39
Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition
Results of Operations
(Tables present dollars in millions, except per-share data)
General
Management’s discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to the results of operations and financial position of our consolidated company. This discussion and analysis should be read in conjunction with the consolidated condensed financial statements and accompanying footnotes in Part I, Item 1 of this Quarterly Report on Form 10-Q. Certain statements in this Part I, Item 2 of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" in this Quarterly Report on Form 10-Q and “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements.
Executive Overview
This section provides an overview of our financial results, recent product and late-stage pipeline developments, and other matters affecting our company and the pharmaceutical industry. Earnings per share (EPS) data are presented on a diluted basis.
COVID-19 Pandemic
In response to the COVID-19 pandemic, we have focused on maintaining a reliable supply of our medicines; reducing the strain on the medical system; developing treatments for COVID-19; protecting the health, safety, and well-being of our employees; supporting our communities; and ensuring affordability of and access to our medicines, particularly insulin.
We have experienced negative impacts to our underlying business due to the COVID-19 pandemic, including decreases in new prescriptions, changes in payer segment mix, and the increased use of patient affordability programs in the United States (U.S.). Additionally, we have experienced, and may continue to experience if the COVID-19 pandemic undergoes resurgent or more severe waves, decreased demand as a result of lack of normal access and fewer in-person interactions by patients and our employees with the healthcare system. Prescriptions in most of our therapeutic areas have returned to pre-COVID-19 pandemic levels in the U.S., and healthcare systems in most of our major markets have largely resumed normal operations as of September 30, 2021. While a majority of in-person interactions by our employees with the healthcare system have resumed, we may decide to halt such activity in the future and, in those cases, expect to resume such interactions as it is safe to do so and in compliance with applicable guidance and requirements. We may experience additional pricing pressures resulting from the financial strain of the COVID-19 pandemic on government-funded healthcare systems around the world. In addition, if the COVID-19 pandemic experiences resurgent or more severe waves, our ability to commercialize some assets in our product pipeline could be delayed or otherwise adversely affected.
Since the start of the pandemic we have worked with a variety of organizations, including governmental agencies, to facilitate access to our COVID-19 therapies in various countries. The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorizations (EUA) for bamlanivimab and bamlanivimab and etesevimab administered together for higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19 and for baricitinib for treatment with or without remdesivir in hospitalized COVID-19 patients. In April 2021, the FDA subsequently revoked the EUA for bamlanivimab alone. In the third quarter of 2021, the FDA expanded the EUA for bamlanivimab and etesevimab administered together to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection.
40
We have, and will continue to, face unique risks and uncertainties in our development, manufacture, and uptake of potential treatments for COVID-19, including vulnerability to supply chain disruptions, higher manufacturing costs, difficulties in manufacturing appropriate quantities of our therapies, heightened regulatory scrutiny of our manufacturing practices, restrictions on administration that limit widespread and timely access to our therapies, and risks related to handling, return, and/or refund of product after delivery by us. Expedited authorization processes, including our EUA for bamlanivimab and etesevimab administered together, have allowed restricted distribution of products with less than typical safety and efficacy data, and additional data that become available have and may further call into question the safety or effectiveness of our COVID-19 therapies. Additionally, the availability of superior or competitive therapies, including therapies that can be administered more easily, or preventative measures, such as vaccines, coupled with the transient nature of pandemics, have and could further negatively impact or eliminate demand for our COVID-19 therapies. Mutations or the spread of other variants of the coronavirus have in some cases impacted the effectiveness of our COVID-19 therapies, and may further render our therapies more or less effective or ineffective. In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations, including our compliance with Good Manufacturing Practices (cGMP), quality assurance, and similar regulations relating to our manufacture of COVID-19 therapies and other medicines. Any of these risks could prevent us from recouping our substantial investments in the research, development, and manufacture of our COVID-19 therapies. These risks could also affect other aspects of our business, including potentially resulting in delays or denials in the approval or launch of other products.
Our ability to continue to operate without significant negative impacts will in part depend on our ability to protect our employees and our supply chain. We have taken steps to protect our employees worldwide, with particular measures in place for those working in our manufacturing sites and distribution facilities. Effective November 2021, we are requiring COVID-19 vaccinations as a condition of employment in the U.S. and Puerto Rico. We have been able to largely maintain our normal operations. However, uncertainty resulting from the COVID-19 pandemic and its effects, including as may relate to our COVID-19 vaccination policy, could have an adverse impact on our manufacturing operations, global supply chain, and distribution systems, which could impact our ability to produce and distribute our products and the ability of third parties on which we rely to fulfill their obligations to us, and could increase our expenses if the COVID-19 pandemic experiences resurgent or more severe waves.
Although the COVID-19 pandemic has affected our operations and demand for our products, it has not negatively impacted our liquidity position. We expect to continue to generate cash flows to meet our short-term liquidity needs and to have access to liquidity via the short-term and long-term debt markets. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021, we have incurred a net inventory impairment charge related to our COVID-19 antibodies during the nine months ended September 30, 2021, primarily due to the combination of changes to current and forecasted demand from the U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies. We could experience additional impairments of our assets, including inventory related to our COVID-19 antibodies, or significant changes in the fair value of our assets due to the COVID-19 pandemic, including as a result of the factors discussed above.
See “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 for additional information on risk factors that could impact our results.
41
Financial Results
The following table summarizes our key operating results:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||||||||
| 2021 | 2020 | Percent Change | 2021 | 2020 | Percent Change | ||||||||||||||||||||||||||||||
| Revenue | $ | 6,772.8 | $ | 5,740.6 | 18 | $ | 20,318.5 | $ | 17,099.8 | 19 | |||||||||||||||||||||||||
| Gross margin | 5,342.0 | 4,414.2 | 21 | 15,055.9 | 13,336.3 | 13 | |||||||||||||||||||||||||||||
| Gross margin as a percent of revenue | 78.9 | % | 76.9 | % | 74.1 | % | 78.0 | % | |||||||||||||||||||||||||||
| Operating expenses | $ | 3,286.8 | $ | 3,034.5 | 8 | $ | 9,906.1 | $ | 8,815.0 | 12 | |||||||||||||||||||||||||
| Acquired in-process research and development (IPR&D) | 174.0 | — | NM | 498.3 | 294.1 | 69 | |||||||||||||||||||||||||||||
| Asset impairment, restructuring, and other special charges | — | 101.4 | NM | 211.6 | 161.3 | 31 | |||||||||||||||||||||||||||||
| Net income | 1,110.1 | 1,208.4 | (8) | 3,855.6 | 4,076.9 | (5) | |||||||||||||||||||||||||||||
| EPS | 1.22 | 1.33 | (8) | 4.23 | 4.47 | (5) | |||||||||||||||||||||||||||||
NM - not meaningful
Revenue increased for the three and nine months ended September 30, 2021, primarily driven by increased volume. Operating expenses, defined as the sum of research and development and marketing, selling, and administrative expenses, increased for the three months ended September 30, 2021, primarily driven by higher development expenses for late-stage assets. Operating expenses increased for the nine months ended September 30, 2021, primarily driven by higher development expenses for late-stage assets and higher research and development expenses for COVID-19 therapies, as well as higher marketing expenses. The decrease in net income and EPS for the three and nine months ended September 30, 2021 was primarily driven by higher operating expenses and a reduction in other-net, (income) expense, partially offset by higher gross margin.
The following highlighted items also affect comparisons of our financial results for the three and nine months ended September 30, 2021 and 2020:
2021
Cost of Sales (See Note 5 to the consolidated condensed financial statements)
•We recognized a net inventory impairment charge related to our COVID-19 antibodies of $435.1 million for the nine months ended September 30, 2021. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.
Acquired IPR&D (See Note 3 to the consolidated condensed financial statements)
•We recognized acquired IPR&D charges of $174.0 million and $498.3 million for the three and nine months ended September 30, 2021, respectively. The charges for the three months ended September 30, 2021 were related to business development transactions with Protomer Technologies Inc. (Protomer), Kumquat Biosciences Inc. (Kumquat), Lycia Therapeutics, Inc. (Lycia), and ProQR Therapeutics N.V. (ProQR). The charges for the nine months ended September 30, 2021 also included charges related to business development transactions with Rigel Pharmaceuticals, Inc. (Rigel), Precision BioSciences, Inc. (Precision), Merus N.V. (Merus), MiNA Therapeutics Limited (MiNA), and Asahi Kasei Pharma Corporation (Asahi).
Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)
•We recognized charges of $211.6 million for the nine months ended September 30, 2021, primarily related to an intangible asset impairment resulting from the sale of the rights to Qbrexza®, as well as acquisition and integration costs associated with the acquisition of Prevail Therapeutics Inc. (Prevail).
42
Other-Net, (Income) Expense (See Note 6 to the consolidated condensed financial statements)
•We recognized a debt extinguishment loss of $405.2 million related to the repurchase of debt for the three and nine months ended September 30, 2021.
•We recognized net investment (losses) gains on equity securities of ($246.8 million) and $270.1 million for the three and nine months ended September 30, 2021, respectively.
2020
Acquired IPR&D (See Note 3 to the consolidated condensed financial statements)
•We recognized acquired IPR&D charges of $294.1 million for the nine months ended September 30, 2020, related to the acquisition of Petra Pharma Corporation (Petra), as well as business development transactions with Sitryx Therapeutics Limited (Sitryx), AbCellera Biologics Inc. (AbCellera), Evox Therapeutics Limited (Evox), and Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences).
Asset Impairment, Restructuring, and Other Special Charges (See Note 5 to the consolidated condensed financial statements)
•We recognized charges of $101.4 million and $161.3 million for the three and nine months ended September 30, 2020, respectively, primarily related to severance costs incurred as a result of actions taken worldwide to reduce our cost structure.
Other-Net, (Income) Expense (See Note 6 to the consolidated condensed financial statements)
•We recognized net investment gains on equity securities of $141.7 million and $905.1 million for the three and nine months ended September 30, 2020, respectively.
Late-Stage Pipeline
Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. We currently have approximately 45 candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.
The following new molecular entities (NMEs) are currently in Phase III clinical trials or have been submitted for regulatory review or have received first regulatory approval in the U.S., Europe, or Japan in 2021. In addition, the following table includes certain NMEs currently in Phase I or Phase II clinical trials. The following table reflects the status of these NMEs, including certain other developments since January 1, 2021.
| Compound | Indication | Status | Developments | ||||||||
| COVID-19 Therapies | |||||||||||
| Bamlanivimab administered alone | COVID-19 | Emergency Use Authorization(1) | Announced in the first quarter of 2021 that a Phase III trial met the primary and all key secondary endpoints. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion in the first quarter of 2021. In the second quarter of 2021 the FDA revoked the EUA for bamlanivimab alone in the U.S. | ||||||||
| Bamlanivimab and etesevimab administered together | COVID-19 | Emergency Use Authorization | Announced in the first quarter of 2021 that Phase III trials met the primary and all key secondary endpoints. Additional Phase III trial is ongoing. The FDA granted EUA for higher-risk patients recently diagnosed with mild-to-moderate COVID-19 in the first quarter of 2021. In the third quarter of 2021 the FDA expanded the EUA to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection. The EMA's CHMP issued a positive scientific opinion in the first quarter of 2021. Submitted in Europe in the first quarter of 2021. Announced a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses in the third quarter of 2021. | ||||||||
| Bamlanivimab, etesevimab and bebtelovimab (LY-CoV1404) administered together | COVID-19 | Phase II | Phase II trial initiated in the second quarter of 2021. | ||||||||
43
| Compound | Indication | Status | Developments | ||||||||
VIR-7831 and bamlanivimab administered together(2) | COVID-19 | Phase II | Phase II trial initiated in the first quarter of 2021. | ||||||||
| Endocrinology | |||||||||||
| Tirzepatide | Type 2 diabetes | Submitted | Announced in the first and second quarters of 2021 that Phase III trials met the primary and key secondary endpoints. Submitted in the U.S. using a priority review voucher and in Europe in October 2021. Additional Phase III trials are ongoing. | ||||||||
| Heart failure with preserved ejection fraction | Phase III | Phase III trial initiated in the second quarter of 2021. | |||||||||
| Obesity | Phase III trials are ongoing. | ||||||||||
| Nonalcoholic steatohepatitis | Phase II | Phase II trial is ongoing. | |||||||||
| Basal Insulin-Fc | Type 1 and 2 diabetes | Phase II | Phase II trials are ongoing. | ||||||||
| GGG Tri-Agonist | Obesity | Phase II | Phase II trials initiated in the second quarter of 2021. | ||||||||
| Type 2 diabetes | |||||||||||
| GLP-1R NPA | Obesity | Phase II | Phase II trials initiated in the third quarter of 2021. | ||||||||
| Type 2 diabetes | |||||||||||
| Immunology | |||||||||||
Lebrikizumab(3) | Atopic dermatitis | Phase III | Granted FDA Fast Track designation(4). Announced in the third quarter of 2021 that Phase III trials met primary and all key secondary endpoints. Additional Phase III trials are ongoing. | ||||||||
| Mirikizumab | Crohn's disease | Phase III | Phase III trials are ongoing. | ||||||||
| Ulcerative colitis | Announced in the first quarter of 2021 that a Phase III trial met the primary and key secondary endpoints. Additional Phase III trials are ongoing. | ||||||||||
| Psoriasis | Not pursuing submission | Announced in the second quarter of 2021 that we do not plan to pursue submission. | |||||||||
| CXCR1/2 Ligands Monoclonal Antibody | Hidradenitis suppurativa | Phase II | Phase II trial is ongoing. | ||||||||
| IL-2 Conjugate | Systemic lupus erythematosus | Phase II | Phase II trial is ongoing. | ||||||||
| Ulcerative colitis | Phase II trial initiated in the second quarter of 2021. | ||||||||||
| PD-1 MAB Agonist | Rheumatoid arthritis | Phase II | Phase II trial initiated in the first quarter of 2021. | ||||||||
| Neuroscience | |||||||||||
| Donanemab | Early Alzheimer’s disease | Submission initiated | Announced in the first quarter of 2021 that a Phase II trial met the primary endpoint and that we expanded a Phase II trial to become a Phase III trial. Granted FDA Breakthrough Therapy designation(5) in the second quarter of 2021. Initiated a rolling submission in the U.S. for accelerated approval in the third quarter of 2021. Additional Phase III trials are ongoing. | ||||||||
| Solanezumab | Preclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | ||||||||
| Epiregulin/TGFα MAB | Chronic pain | Phase II | Phase II trials are ongoing. | ||||||||
44
| Compound | Indication | Status | Developments | ||||||||
| GBA1 Gene Therapy (PR001) | Parkinson's disease | Phase II | Acquired in the Prevail acquisition in the first quarter of 2021. Granted FDA Fast Track designation(4). Phase II trials are ongoing. | ||||||||
| GRN Gene Therapy (PR006) | Frontotemporal dementia | Phase II | |||||||||
| PACAP38 Antibody | Chronic pain | Phase II | Phase II trial is ongoing. | ||||||||
| SSTR4 Agonist | Chronic pain | Phase II | Phase II trials are ongoing. | ||||||||
| TRPA1 Antagonist | Pain | Phase II | Phase II trials initiated in October 2021. | ||||||||
Tanezumab(6) | Osteoarthritis pain | Discontinued | In October 2021, in collaboration with Pfizer, we discontinued the global clinical development program following receipt of a Complete Response Letter from the FDA and a negative opinion from the EMA's CHMP. | ||||||||
| Cancer pain | |||||||||||
| Zagotenemab | Alzheimer’s disease | Discontinued | Announced in October 2021 that a Phase II trial did not meet the primary endpoint and we will discontinue development. | ||||||||
| Oncology | |||||||||||
Selpercatinib (Retevmo®) | Thyroid cancer | Launched(7) | Launched in Europe in the first quarter of 2021. Approved in Japan in the third quarter of 2021. Phase III trials are ongoing. | ||||||||
| Lung cancer | |||||||||||
Sintilimab injection(8) | Lung cancer | Submitted | In collaboration with Innovent, submitted in the U.S. in the second quarter of 2021. | ||||||||
| Imlunestrant | ER+HER2-metastic breast cancer | Phase III | Phase III trial initiated in October 2021. | ||||||||
| Pirtobrutinib (LOXO-305) | Chronic lymphocytic leukemia | Phase III | Phase III trials initiated in the first and third quarters of 2021. | ||||||||
| Mantle cell lymphoma | Phase III | Phase III trial initiated in the second quarter of 2021. | |||||||||
| B-cell malignancies | Phase II | Phase II trial initiated in the second quarter of 2021. | |||||||||
(1) EUAs remain active for certain countries outside of the U.S.
(2) In collaboration with Vir Biotechnology, Inc. and GlaxoSmithKline plc.
(3) In collaboration with Almirall, S.A. (Almirall) in Europe.
(4) Fast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.
(5) Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.
(6) In collaboration with Pfizer, Inc (Pfizer).
(7) Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase III trials.
(8) In collaboration with Innovent Biologics, Inc. (Innovent).
45
Our pipeline also contains several new indication line extension (NILEX) products. The following certain NILEX products are currently in Phase II or Phase III clinical testing, have been submitted for regulatory review, or have received first regulatory approval in the U.S., Europe, or Japan for use in the indication described in 2021. The following table reflects the status of certain NILEX products, including certain other developments since January 1, 2021:
| Compound | Indication | Status | Developments | ||||||||
| Endocrinology | |||||||||||
Empagliflozin (Jardiance®)(1) | Heart failure with reduced ejection fraction | Launched | Launched in the U.S. and Europe in the third quarter of 2021. | ||||||||
| Heart failure with preserved ejection fraction | Submitted | Granted FDA Fast Track designation(2). In the third quarter of 2021 the FDA granted Breakthrough Therapy designation(3). Announced in the third quarter of 2021 that a Phase III trial met the primary endpoint. Submitted in the U.S. and Europe in October 2021. | |||||||||
| Chronic kidney disease | Phase III | Granted FDA Fast Track designation(2). Phase III trials are ongoing. | |||||||||
| Immunology | |||||||||||
Baricitinib (Olumiant®) | Atopic dermatitis | Launched | Launched in Europe and Japan. Announced in the third quarter of 2021 that the FDA will not meet the Prescription Drug User Fee Act action date for the submission in the U.S. | ||||||||
| COVID-19 | Emergency Use Authorization(4) | Announced in the second quarter of 2021 that a Phase III trial evaluating baricitinib 4 mg once daily plus standard of care did not meet the primary endpoint, but did result in a significant reduction in death. In the third quarter of 2021, the FDA broadened the EUA for baricitinib to allow for treatment with or without remdesivir. | |||||||||
| Alopecia areata | Submitted | Granted FDA Breakthrough Therapy designation(3). Announced in the first, second and third quarters of 2021 that Phase III trials met the primary and all key secondary endpoints. Submitted in Europe and Japan in the third quarter of 2021. We intend to submit to the FDA by the end of 2021. | |||||||||
| Systemic lupus erythematosus | Phase III | Phase III trials are ongoing. | |||||||||
| Oncology | |||||||||||
Abemaciclib (Verzenio®) | HR+, HER2- Adjuvant breast cancer | Launched | Announced in the first quarter of 2021 patient-reported outcomes in combination with standard adjuvant endocrine therapy. Submitted in Japan in the first quarter of 2021. Launched in the U.S. in October 2021. | ||||||||
| HR+, HER2+ Adjuvant breast cancer | Phase III | Phase III trial initiated in the second quarter of 2021. | |||||||||
| Prostate cancer | Phase III | Phase III trial initiated in the third quarter of 2021. | |||||||||
(1) In collaboration with Boehringer Ingelheim.
(2) Fast Track designation is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs.
(3) Breakthrough Therapy designation is designed to expedite the development and review of potential medicines that are intended to treat a serious condition where preliminary clinical evidence indicates that the treatment may demonstrate substantial improvement over available therapy on a clinically significant endpoint.
(4) The FDA granted EUA for treatment with or without remdesivir in hospitalized COVID-19 patients.
46
Other Matters
Patent Matters
We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings.
Our vitamin regimen patents for Alimta® expired in major European countries and Japan in June 2021. We have faced, and remain exposed to, generic competition following the loss of exclusivity in major European countries and Japan, which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels. In the U.S., we expect the vitamin regimen patent for Alimta to provide us with patent protection through May 2022. However, we and Eagle Pharmaceuticals, Inc. (Eagle) reached an agreement in December 2019 to settle all pending U.S. patent litigation, allowing Eagle a limited initial entry into the market with its product starting February 2022 (up to an approximate three-week supply) and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition in the U.S. following the loss of patent exclusivity will cause a rapid and severe decline in revenue and will have a material adverse effect on our consolidated results of operations and cash flows. See Note 9 to the consolidated condensed financial statements for a more detailed account of the legal proceedings currently pending regarding, among others, our Alimta patents.
Our compound patent for Humalog® (insulin lispro) has expired in major markets. Global regulators have different legal pathways to approve similar versions of insulin lispro. A competitor launched a similar version of insulin lispro in certain European markets in 2017 and in the U.S. in the second quarter of 2018. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue; however, we expect additional pricing pressure and some loss of market share that would continue over time.
Our formulation and use patents for Forteo® have expired in major markets. We expect further decline in revenue as a result of the entry of generic and biosimilar competition due to the loss of patent exclusivity in major markets.
Our compound patent for Cymbalta® expired in Japan in January 2020. We have faced, and remain exposed to, generic competition following the loss of exclusivity, which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels.
Foreign Currency Exchange Rates
As a global company with substantial operations outside the U.S., we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan. While we manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a substantial impact, either positive or negative, on our revenue, cost of sales, and operating expenses. While there is uncertainty in the future movements in foreign exchange rates, fluctuations in these rates could adversely impact our future consolidated results of operations and cash flows.
Trends Affecting Pharmaceutical Pricing, Reimbursement, Access, and Other Regulatory Matters
Global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate, as well as worldwide cost containment efforts by governmental authorities. Such measures may include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts. In addition, consolidation of private payors in the U.S. has significantly impacted the market for pharmaceuticals by increasing payor leverage in negotiating manufacturer price concessions and pharmacy reimbursement rates. We expect that these actions may intensify and could particularly affect certain products, such as insulin, as governments manage and emerge from the pandemic, which could adversely affect our business. It is not possible to predict the potential adverse impact to us or the general pharmaceutical industry of continued cost containment efforts.
In addition, evolving regulatory priorities have intensified governmental scrutiny of our operations and our industry, including with respect to cGMP, quality assurance, and similar regulations, and increased focus on business combinations in our industry. Any regulatory issues concerning these matters could lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in the approvals of new products pending resolution of the issues, impediments to the completion of business combinations, and reputational harm, any of which would adversely affect our business.
See “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020. See also Note 9 to the consolidated condensed financial statements.
47
Tax Matters
We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations could affect our effective tax rate, results of operations, and cash flows. Countries around the world, including the U.S., are actively considering and enacting tax law changes. Tax proposals introduced by Congress and the Biden administration contain significant changes, including increases to the tax rates at which both domestic and foreign income of U.S. companies would be taxed. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax policy in countries in which we operate. In addition, global tax authorities routinely examine our tax returns and are expected to become more aggressive in their examinations of profit allocations among jurisdictions, which could adversely impact our future consolidated results of operations and cash flows.
Acquisitions
We strategically invest in external research and technologies that we believe to complement and strengthen our own efforts. These investments can take many forms, including acquisitions, strategic alliances, collaborations, investments, and licensing arrangements. We view our business development activity as an important way to achieve our strategies, as we seek to bolster our pipeline and enhance shareholder value. We continuously evaluate business development transactions that have the potential to strengthen our business.
In February 2020, we acquired all shares of Dermira, Inc. for a purchase price of $849.3 million, net of cash acquired. Under the terms of the agreement, we acquired lebrikizumab, a novel, investigational, monoclonal antibody being evaluated for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track designation from the FDA. We also acquired Qbrexza cloth, a medicated cloth for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). During the nine months ended September 30, 2021, we sold the rights to Qbrexza. See Note 5 to the consolidated condensed financial statements for additional information.
In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions, upon the first regulatory approval of a Prevail product in one of the following countries: U.S., Japan, United Kingdom, Germany, France, Italy, or Spain. Under the terms of the agreement, we acquired a gene therapy program for patients with neurodegenerative diseases.
See Note 3 to the consolidated condensed financial statements for further discussion regarding our recent acquisitions.
48
Revenue
The following table summarizes our revenue activity by region:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||||||||
| 2021 | 2020 | Percent Change | 2021 | 2020 | Percent Change | |||||||||||||||||||||||||||
| U.S. | $ | 3,989.6 | $ | 3,161.4 | 26 | $ | 11,635.1 | $ | 9,631.4 | 21 | ||||||||||||||||||||||
| Outside U.S. | 2,783.3 | 2,579.3 | 8 | 8,683.4 | 7,468.5 | 16 | ||||||||||||||||||||||||||
| Revenue | $ | 6,772.8 | $ | 5,740.6 | 18 | $ | 20,318.5 | $ | 17,099.8 | 19 | ||||||||||||||||||||||
Numbers may not add due to rounding.
The following are components of the change in revenue compared with the prior year:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2021 vs. 2020 | 2021 vs. 2020 | ||||||||||||||||||||||
| U.S. | Outside U.S. | Consolidated | U.S. | Outside U.S. | Consolidated | ||||||||||||||||||
| Volume | 22 | % | 11 | % | 17 | % | 22 | % | 15 | % | 19 | % | |||||||||||
| Price | 4 | (4) | — | (1) | (3) | (2) | |||||||||||||||||
| Foreign exchange rates | — | 1 | 1 | — | 4 | 2 | |||||||||||||||||
| Percent change | 26 | % | 8 | % | 18 | % | 21 | % | 16 | % | 19 | % | |||||||||||
Numbers may not add due to rounding.
In the U.S. for the three and nine months ended September 30, 2021, the increase in volume was primarily driven by COVID-19 therapies, Trulicity®, and Taltz®. In the U.S. for the three months ended September 30, 2021, the increase in realized prices was driven by lower utilization in the 340B program, unfavorable changes to estimates for rebates and discounts for Trulicity in the three months ended September 30, 2020, and modest list prices increases, partially offset by increased rebates to maintain access for products across the business. U.S. price performance was not a major driver during the nine months ended September 30, 2021, as increased utilization in more highly-rebated segments was largely offset by lower utilization in the 340B program, primarily for the diabetes portfolio.
Outside the U.S. for the three and nine months ended September 30, 2021, the increase in volume was primarily driven by COVID-19 therapies, Trulicity, Verzenio, and Taltz. Outside the U.S. for the nine months ended September 30, 2021, the increase in volume was also driven by the sale of our rights to Cialis® in China.
49
The following table summarizes our revenue activity by product for the three months ended September 30, 2021 and 2020:
| Three Months Ended September 30, | |||||||||||||||||||||||||||||
| 2021 | 2020 | ||||||||||||||||||||||||||||
| Product | U.S. | Outside U.S. | Total | Total | Percent Change | ||||||||||||||||||||||||
| Trulicity | $ | 1,201.4 | $ | 398.8 | $ | 1,600.1 | $ | 1,106.6 | 45 | ||||||||||||||||||||
Humalog (1) | 347.3 | 279.4 | 626.7 | 656.9 | (5) | ||||||||||||||||||||||||
| Taltz | 422.2 | 170.9 | 593.1 | 454.5 | 30 | ||||||||||||||||||||||||
| Alimta | 297.2 | 159.8 | 457.0 | 578.0 | (21) | ||||||||||||||||||||||||
Olumiant (2) | 194.0 | 212.9 | 406.9 | 162.0 | NM | ||||||||||||||||||||||||
Jardiance (3) | 221.2 | 169.2 | 390.4 | 310.8 | 26 | ||||||||||||||||||||||||
| Verzenio | 199.6 | 135.9 | 335.5 | 234.4 | 43 | ||||||||||||||||||||||||
Humulin® | 193.4 | 93.4 | 286.7 | 305.9 | (6) | ||||||||||||||||||||||||
Cyramza® | 84.8 | 168.6 | 253.4 | 252.7 | — | ||||||||||||||||||||||||
COVID-19 antibodies (4) | 215.5 | 1.6 | 217.1 | — | NM | ||||||||||||||||||||||||
| Forteo | 109.6 | 91.3 | 200.9 | 266.9 | (25) | ||||||||||||||||||||||||
Basaglar® | 114.7 | 78.1 | 192.8 | 248.2 | (22) | ||||||||||||||||||||||||
Emgality® | 99.9 | 40.1 | 140.0 | 91.5 | 53 | ||||||||||||||||||||||||
Erbitux® | 114.0 | 20.3 | 134.3 | 136.4 | (2) | ||||||||||||||||||||||||
| Cymbalta | 7.0 | 125.1 | 132.0 | 186.6 | (29) | ||||||||||||||||||||||||
| Cialis | (6.5) | 137.4 | 130.9 | 162.5 | (19) | ||||||||||||||||||||||||
Tyvyt® | — | 125.6 | 125.6 | 84.4 | 49 | ||||||||||||||||||||||||
Zyprexa® | 13.0 | 88.7 | 101.7 | 112.7 | (10) | ||||||||||||||||||||||||
| Other products | 161.5 | 286.3 | 447.7 | 389.6 | 15 | ||||||||||||||||||||||||
| Revenue | $ | 3,989.6 | $ | 2,783.3 | $ | 6,772.8 | $ | 5,740.6 | 18 | ||||||||||||||||||||
Numbers may not add due to rounding.
NM - not meaningful
(1) Humalog revenue includes insulin lispro.
(2) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.
(3) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(4) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.
50
The following table summarizes our revenue activity by product for the nine months ended September 30, 2021 and 2020:
| Nine Months Ended September 30, | |||||||||||||||||||||||||||||
| 2021 | 2020 | ||||||||||||||||||||||||||||
| Product | U.S. (1) | Outside U.S. | Total | Total | Percent Change | ||||||||||||||||||||||||
| Trulicity | $ | 3,465.7 | $ | 1,122.5 | $ | 4,588.2 | $ | 3,565.7 | 29 | ||||||||||||||||||||
Humalog (1) | 1,009.0 | 842.3 | 1,851.3 | 1,907.8 | (3) | ||||||||||||||||||||||||
| Alimta | 911.9 | 714.7 | 1,626.6 | 1,677.2 | (3) | ||||||||||||||||||||||||
| Taltz | 1,071.6 | 493.8 | 1,565.4 | 1,293.2 | 21 | ||||||||||||||||||||||||
COVID-19 antibodies (2) | 949.5 | 226.7 | 1,176.2 | — | NM | ||||||||||||||||||||||||
Jardiance (3) | 566.8 | 492.1 | 1,058.9 | 840.3 | 26 | ||||||||||||||||||||||||
| Verzenio | 582.1 | 363.7 | 945.8 | 631.1 | 50 | ||||||||||||||||||||||||
| Humulin | 633.5 | 290.3 | 923.8 | 935.2 | (1) | ||||||||||||||||||||||||
Olumiant (4) | 236.5 | 572.6 | 809.1 | 446.7 | 81 | ||||||||||||||||||||||||
| Cyramza | 266.3 | 496.3 | 762.5 | 748.4 | 2 | ||||||||||||||||||||||||
| Basaglar | 423.3 | 226.8 | 650.1 | 842.3 | (23) | ||||||||||||||||||||||||
| Forteo | 330.1 | 287.7 | 617.8 | 791.9 | (22) | ||||||||||||||||||||||||
| Cialis | (3.1) | 541.8 | 538.7 | 486.2 | 11 | ||||||||||||||||||||||||
| Cymbalta | 30.3 | 454.0 | 484.3 | 576.9 | (16) | ||||||||||||||||||||||||
| Emgality | 313.5 | 102.2 | 415.7 | 252.9 | 64 | ||||||||||||||||||||||||
| Erbitux | 357.7 | 45.9 | 403.7 | 396.7 | 2 | ||||||||||||||||||||||||
| Tyvyt | — | 340.2 | 340.2 | 205.9 | 65 | ||||||||||||||||||||||||
| Zyprexa | 28.3 | 264.5 | 292.8 | 307.7 | (5) | ||||||||||||||||||||||||
| Other products | 462.1 | 805.1 | 1,267.3 | 1,193.7 | 6 | ||||||||||||||||||||||||
| Revenue | $ | 11,635.1 | $ | 8,683.4 | $ | 20,318.5 | $ | 17,099.8 | 19 | ||||||||||||||||||||
Numbers may not add due to rounding.
NM - not meaningful
(1) Humalog revenue includes insulin lispro.
(2) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.
(3) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
(4) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.
Revenue of Trulicity, a treatment for type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, increased 52 percent and 30 percent in the U.S. during the three and nine months ended September 30, 2021, respectively, driven by increased demand and, to a lesser extent, higher realized prices due to segment mix, including lower utilization in the 340B program, and modest list price increases, partially offset by increased rebates to maintain access. Trulicity's higher realized prices in the U.S. during the three months ended September 30, 2021 were also due to unfavorable changes to estimates for rebates and discounts in the three months ended September 30, 2020. Revenue outside the U.S. increased 26 percent during the three and nine months ended September 30, 2021, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.
51
Revenue of Humalog, an injectable human insulin analog for the treatment of diabetes, decreased 11 percent and 6 percent in the U.S. during the three and nine months ended September 30, 2021, respectively, driven by lower realized prices, partially offset by increased demand. Revenue outside the U.S. increased 5 percent during the three months ended September 30, 2021, driven by the favorable impact of foreign exchange rates and increased volume, partially offset by lower realized prices. Revenue outside the U.S. increased 1 percent during the nine months ended September 30, 2021, primarily driven by the favorable impact of foreign exchange rates, largely offset by decreased volume. While it is difficult to estimate the severity of the impact of insulin lispro products entering the market, we do not expect and have not experienced a rapid and severe decline in revenue. However, due to the impact of competition and due to pricing pressure in the U.S. and some international markets, we expect some price decline and loss of market share to continue over time.
Revenue of Alimta, a treatment for various cancers, increased 2 percent in the U.S. during the three months ended September 30, 2021, primarily driven by higher realized prices, partially offset by decreased demand and customer buying patterns. Revenue decreased 2 percent in the U.S. during the nine months ended September 30, 2021, primarily driven by decreased demand, partially offset by higher realized prices. Revenue outside the U.S. decreased 44 percent during the three months ended September 30, 2021, primarily driven by decreased volume due to entry of generic competition and, to a lesser extent, lower realized prices. Revenue outside the U.S. decreased 4 percent during the nine months ended September 30, 2021, driven by lower realized prices and decreased volume, partially offset by the favorable impact of foreign exchange rates. We have faced and remain exposed to generic competition following the loss of exclusivity in major European countries and Japan in June 2021, which has eroded revenue and is likely to continue to rapidly and severely erode revenue from current levels. We expect the limited entry of generic competition in the U.S. starting February 2022 and subsequent unlimited entry starting April 2022. We expect that the entry of generic competition following the loss of exclusivity in the U.S. will cause a rapid and severe decline in revenue. See "Executive Overview - Other Matters- Patent Matters" for more information.
Revenue of Taltz, a treatment for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis, increased 29 percent and 14 percent in the U.S. during the three and nine months ended September 30, 2021, respectively, primarily driven by increased demand, partially offset by lower realized prices due to increased rebates to gain commercial access. Taltz's lower realized prices in the U.S. during the three months ended September 30, 2021 were also driven by unfavorable segment mix, partially offset by changes to estimates for rebates and discounts. Revenue outside the U.S. increased 33 percent and 41 percent during the three and nine months ended September 30, 2021, respectively, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.
Revenue of COVID-19 antibodies, treatments that were authorized pursuant to EUAs for mild to moderate COVID-19 for higher-risk patients and for post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection, was $215.5 million and $949.5 million in the U.S. during the three and nine months ended September 30, 2021, respectively. Revenue outside the U.S. was $1.6 million and $226.7 million during the three and nine months ended September 30, 2021, respectively. The availability of superior or competitive therapies, including therapies that can be administered more easily, or preventative measures, such as vaccines, coupled with the transient nature of pandemics, have and could further negatively impact or eliminate demand for these COVID-19 antibodies. In addition, mutations or the spread of other variants of the coronavirus have in some cases impacted the effectiveness of our COVID-19 antibodies, and may further render our antibodies more or less effective or ineffective.
Revenue of Jardiance, a treatment for type 2 diabetes, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease, and to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction, increased 35 percent and 25 percent in the U.S. during the three and nine months ended September 30, 2021, respectively, primarily driven by increased demand. Revenue outside the U.S. increased 15 percent during the three months ended September 30, 2021, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates. Revenue outside the U.S. increased 27 percent during the nine months ended September 30, 2021, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates. See Note 4 to the consolidated condensed financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.
52
Revenue of Verzenio, a treatment for HR+, HER2- metastatic breast cancer and high risk early breast cancer, increased 26 percent in the U.S. during the three months ended September 30, 2021, driven by increased demand, partially offset by lower realized prices. Revenue of Verzenio increased 35 percent in the U.S. during the nine months ended September 30, 2021, primarily driven by increased demand. Revenue outside the U.S. increased 80 percent and 81 percent during the three and nine months ended September 30, 2021, respectively, primarily driven by increased volume.
Revenue of Humulin, an injectable human insulin for the treatment of diabetes, decreased 10 percent and 1 percent in the U.S. during the three and nine months ended September 30, 2021, respectively, driven by lower realized prices and decreased demand. Revenue outside the U.S. increased 2 percent during the three months ended September 30, 2021, driven by higher realized prices and, to a lesser extent, the favorable impact of foreign exchange rates, largely offset by decreased volume. Revenue outside the U.S. decreased 1 percent during the nine months ended September 30, 2021, driven by decreased volume, largely offset by the favorable impact of foreign exchange rates and higher realized prices.
Revenue of Olumiant, a treatment for adults with moderately-to-severely active rheumatoid arthritis, and of baricitinib, a treatment authorized pursuant to EUA, with or without remdesivir, of hospitalized patients with COVID-19, increased $179.5 million and $197.5 million in the U.S. during the three and nine months ended September 30, 2021, respectively, driven by utilization for the treatment of hospitalized patients with COVID-19 during the third quarter of 2021. Revenue outside the U.S. increased 44 percent and 40 percent during the three and nine months ended September 30, 2021, respectively, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices.
Revenue of Cyramza, a treatment for various cancers, decreased 10 percent and 4 percent in the U.S. during the three and nine months ended September 30, 2021, respectively, primarily driven by decreased demand, partially offset by higher realized prices. Revenue outside the U.S. increased 7 percent and 5 percent for the three and nine months ended September 30, 2021, respectively, driven by increased volume. In addition, the increase in revenue outside the U.S. for the three months ended September 30, 2021 was partially offset by lower realized prices and the unfavorable impact of foreign exchange rates.
53
Gross Margin, Costs, and Expenses
Gross margin as a percent of revenue increased 2.0 percentage points to 78.9 percent and decreased 3.9 percentage points to 74.1 percent for the three and nine months ended September 30 2021, respectively. The increase in gross margin percent for the three months ended September 30, 2021 was primarily due to favorable product mix and favorable effect of foreign exchange rates on international inventories sold. The decrease in gross margin percent for the nine months ended September 30, 2021 was primarily driven by lower gross margin on COVID-19 therapies, including the impact of $435.1 million of a net inventory impairment charge related to our COVID-19 antibodies. As part of our response to the COVID-19 pandemic, and at the request of the U.S. and international governments, we invested in large-scale manufacturing of COVID-19 antibodies at risk, in order to ensure rapid access to patients around the world. As the COVID-19 pandemic has continued to evolve during 2021, we incurred a net inventory impairment charge primarily due to the combination of changes to current and forecasted demand from U.S. and international governments, including changes to our agreement with the U.S. government, and near-term expiry dates of COVID-19 antibodies.
Research and development expenses increased 17 percent to $1.71 billion and 19 percent to $5.07 billion for the three and nine months ended September 30, 2021, respectively. The increase in research and development expenses for the three and nine months ended September 30, 2021 was primarily driven by higher development expenses for late-stage assets. The increase in research and development expenses for the nine months ended September 30, 2021 was also driven by higher research and development expenses for COVID-19 therapies.
Marketing, selling, and administrative expenses increased 1 percent to $1.58 billion and 6 percent to $4.84 billion for the three and nine months ended September 30, 2021, respectively. The increase in marketing, selling, and administrative expenses for the nine months ended September 30, 2021 was primarily driven by lower marketing expenses for the nine months ended September 30, 2020 due to pandemic-related spending reductions.
We recognized $174.0 million and $498.3 million of acquired IPR&D charges for the three and nine months ended September 30, 2021, respectively. The charges for the three months ended September 30, 2021 were related to business development transactions with Protomer, Kumquat, Lycia, and ProQR. The charges for the nine months ended September 30, 2021 also included charges related to business development transactions with Rigel, Precision, Merus, MiNA, and Asahi. We recognized $294.1 million of acquired IPR&D charges for the nine months ended September 30, 2020, related to the acquisition of Petra, as well as business development transactions with Sitryx, AbCellera, Evox, and Junshi Biosciences.
We recognized asset impairment, restructuring, and other special charges of $211.6 million for the nine months ended September 30, 2021, primarily related to an intangible asset impairment resulting from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail. We recognized asset impairment, restructuring, and other special charges of $101.4 million and $161.3 million for the three and nine months ended September 30, 2020, respectively, primarily related to severance costs incurred as a result of actions taken worldwide to reduce our cost structure.
Other–net, (income) expense was expense of $635.9 million and $124.3 million for the three and nine months ended September 30, 2021, respectively, compared with income of $158.9 million and $694.9 million for the three and nine months ended September 30, 2020, respectively. The decrease in other-net, (income) expense for the three months ended September 30, 2021 was driven primarily by a debt extinguishment loss of $405.2 million related to the repurchase of debt and unfavorable mark-to-market adjustments on investments in equity securities during the three months ended September 30, 2021 compared to favorable mark-to-market adjustments on investments in equity securities during the three months ended September 30, 2020. The decrease in other-net, (income) expense for the nine months ended September 30, 2021 was driven by lower favorable mark-to-market adjustments on investments in equity securities and a debt extinguishment loss of $405.2 million related to the repurchase of debt, partially offset by income from patent settlements in Europe for Alimta.
54
The effective tax rate was 10.9 percent for the three months ended September 30, 2021, compared with 15.9 percent for the three months ended September 30, 2020. The effective tax rate was 10.7 percent for the nine months ended September 30, 2021, compared with 14.4 percent for the nine months ended September 30, 2020. The lower effective tax rate for the three months ended September 30, 2021 was primarily due to the income tax impact of a debt extinguishment loss and unfavorable mark-to-market adjustments on investments in equity securities, partially offset by a lower net discrete tax benefit compared to the three months ended September 30, 2020. The lower effective tax rate for the nine months ended September 30, 2021 was primarily due to the income tax impacts of a net inventory impairment charge related to our COVID-19 antibodies and a debt extinguishment loss, as well as higher acquired IPR&D charges and lower favorable mark-to-market adjustments on investments in equity securities compared to the nine months ended September 30, 2020, partially offset by a lower net discrete tax benefit compared to the nine months ended September 30, 2020.
55
Financial Condition and Liquidity
We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements. For a discussion of our capital requirements, see “Management's Discussion and Analysis of Results of Operations and Financial Condition” in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2020.
Cash and cash equivalents increased to $3.79 billion as of September 30, 2021, compared with $3.66 billion as of December 31, 2020. Refer to the consolidated condensed statements of cash flows for additional information on the significant sources and uses of cash for the nine months ended September 30, 2021 and 2020.
In addition to our cash and cash equivalents, we held total investments of $3.39 billion and $2.99 billion as of September 30, 2021 and December 31, 2020, respectively. See Note 6 to the consolidated condensed financial statements for additional information.
In January 2021, we acquired all shares of Prevail for a purchase price that included $22.50 per share in cash (or an aggregate of $747.4 million, net of cash acquired) plus one non-tradable CVR per share. The CVR entitles Prevail stockholders up to an additional $4.00 per share in cash (or an aggregate of approximately $160 million) payable, subject to certain terms and conditions. The acquisition was funded primarily through cash on hand. See Note 3 to the consolidated condensed financial statements for additional information.
As of September 30, 2021, total debt was $17.09 billion, an increase of $490.1 million compared with $16.60 billion as of December 31, 2020. In September 2021, we issued euro-denominated notes consisting of €500.0 million of 1.125 percent fixed-rate notes due in September 2051 and €700.0 million of 1.375 percent fixed-rate notes due in September 2061, with interest to be paid annually, and British pound-denominated notes consisting of £250.0 million of 1.625 percent fixed-rate notes due in September 2043, with interest to be paid annually. We paid $1.91 billion of the net cash proceeds from the offering to purchase and redeem certain higher interest rate U.S. dollar-denominated notes with an aggregate principal amount of $1.50 billion. We used the remaining net proceeds from the offering to prefund certain 2022 debt maturities and for general corporate purposes In addition, in September 2021, we issued euro-denominated notes consisting of €600.0 million of 0.50 percent fixed-rate notes due in September 2033, with interest to be paid annually. The net proceeds from the offering will be used to fund, in whole or in part, eligible projects designed to advance one or more of our environmental, social, and governance objectives. See Note 6 to the consolidated condensed financial statements for additional information.
As of September 30, 2021, we had a total of $5.24 billion of unused committed bank credit facilities, $5.00 billion of which is available to support our commercial paper program. We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs.
During the nine months ended September 30, 2021, we repurchased $500.0 million of shares under our $8.00 billion share repurchase program authorized in June 2018. As of September 30, 2021, we had $500.0 million remaining under this program. In May 2021 we authorized an additional $5.00 billion share repurchase program. There were no shares repurchased under the $5.00 billion share repurchase program during the nine months ended September 30, 2021.
During the nine months ended September 30, 2021, we paid dividends of approximately $2.31 billion, or $2.55 per share, to our shareholders. In October 2021, we declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock. The dividend of approximately $770 million is payable on December 10, 2021 to shareholders of record at the close of business on November 15, 2021.
See "Executive Overview - Other Matters - Patent Matters" for information regarding recent and upcoming losses of patent protection.
Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; various international government funding levels; and fluctuations in interest rates, foreign currency exchange rates (see "Executive Overview - Other Matters - Foreign Currency Exchange Rates"), and fair values of equity securities.
56
Financial Expectations
We have updated certain elements of our 2021 financial guidance on a reported basis.
Earnings per share for 2021 are now expected to be in the range of $6.38 to $6.48.
We now anticipate 2021 revenue to be between $27.2 billion and $27.6 billion. This increase reflects additional revenue from COVID-19 antibodies and the underlying core business. Estimated revenue from COVID-19 antibodies is now expected to be $1.3 billion.
Gross margin as a percent of revenue for 2021 is unchanged and expected to be approximately 75 percent. Research and development expenses for 2021 are unchanged and remain in the range of $6.9 billion to $7.1 billion. Marketing, selling, and administrative expenses for 2021 are unchanged and remain in the range of $6.2 billion to $6.4 billion.
Acquired IPR&D is now expected to be $498.3 million reflecting charges related to business development transactions with Lycia Therapeutics, Inc. and ProQR Therapeutics N.V. recognized during the three months ended September 30, 2021.
Other—net, (income) expense for 2021 is now expected to be expense in the range of $150 million to $250 million, reflecting the impact of a debt extinguishment loss related to the repurchase of debt and unfavorable mark-to-market adjustments on investments in equity securities during the three months ended September 30, 2021.
The effective tax rate for 2021 is now expected to be approximately 11 percent, reflecting primarily the tax impact of the charges associated with a debt extinguishment loss related to the repurchase of debt and acquired IPR&D, as well as unfavorable mark-to-market adjustments on investments in equity securities during the three months ended September 30, 2021.
Available Information on our Website
We make available through our company website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC. The reports we make available include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.
The website link to our SEC filings is investor.lilly.com/financial-information/sec-filings. The information contained in, or that can be accessed through, our website is not a part of, or incorporated by reference in, this Quarterly Report.
57
Item 4. Controls and Procedures
(a)Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) is recorded, processed, summarized, and reported on a timely basis.
Our management, with the participation of David A. Ricks, president and chief executive officer, and Anat Ashkenazi, senior vice president and chief financial officer, evaluated our disclosure controls and procedures (as such terms are defined in our Annual Report on Form 10-K for the year ended December 31, 2020) as of September 30, 2021, and concluded that they were effective.
(b)Changes in Internal Controls. During the third quarter of 2021, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
58
PART II. Other Information
Item 1. Legal Proceedings
We are a party to various currently pending legal actions, government investigations, and environmental proceedings. See Note 9 to the consolidated condensed financial statements for information on various legal proceedings.
This Item should be read in conjunction with "Legal Proceedings" in Part I, Item 3 of our Annual Report on Form 10-K for the year ended December 31, 2020.
Item 1A. Risk Factors
Our material risk factors are disclosed in "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Information relating to the principal market for our common stock and related shareholder matters is described in "Management's Discussion and Analysis of Results of Operations and Financial Condition" in Part II, Item 7 and in "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" in Part III, Item 12 of our Annual Report on Form 10-K for the year ended December 31, 2020.
The following table summarizes the activity related to repurchases of our equity securities during the three months ended September 30, 2021:
| Period | Total Number of Shares Purchased (in thousands) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (in thousands) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in millions) | |||||||||||||||||||
| July 2021 | — | $ | — | — | $ | 5,500.0 | |||||||||||||||||
| August 2021 | — | — | — | 5,500.0 | |||||||||||||||||||
| September 2021 | — | — | — | 5,500.0 | |||||||||||||||||||
| Total | — | — | — | ||||||||||||||||||||
During the three months ended September 30, 2021, we did not repurchase any shares under our $8.00 billion or $5.00 billion share repurchase programs authorized in June 2018 and May 2021, respectively.
59
Item 6. Exhibits
The following documents are filed as a part of this Quarterly Report:
| Exhibit | Description | |||||||
| EXHIBIT 3.1 | ||||||||
| EXHIBIT 3.2 | ||||||||
| EXHIBIT 31.1 | ||||||||
| EXHIBIT 31.2 | ||||||||
| EXHIBIT 32. | ||||||||
| EXHIBIT 101. | Interactive Data Files (embedded within the Inline XBRL document) | |||||||
| EXHIBIT 104. | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |||||||
(i) Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of our consolidated assets are not filed as exhibits to this Quarterly Report. We will furnish a copy of these agreements to the SEC upon request.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| ELI LILLY AND COMPANY | ||||||||
| (Registrant) | ||||||||
| Date: | October 27, 2021 | /s/Anat Ashkenazi | ||||||
| Anat Ashkenazi | ||||||||
| Senior Vice President and Chief Financial Officer | ||||||||
| Date: | October 27, 2021 | /s/Donald A. Zakrowski | ||||||
| Donald A. Zakrowski | ||||||||
| Vice President, Finance, and Chief Accounting Officer | ||||||||
60